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ABSTRACT
Rab and Rho subfamilies of GTPases are functionally linked to intracellular trafficking
and organization of the cytoskeleton respectively. Despite their roles, use of small
molecule inhibitors or activators to map the functionality of these GTPases remains
largely underexplored due to lack of suitable compounds. In this dissertation, we report
on the functional characterization of Rab7 and Rac1 GTPases using small molecules. 2(benzoylcarbamothioylamino)-5,5-dimethyl-4,7- dihydrothieno[2,3-c]pyran-3-carboxylic
acid (PubChem #: CID1067700) has been used to characterize Rab7. Using bead based
flow cytometry, CID1067700 was found to have significant inhibitory potency on Rab7
nucleotide binding with a respective inhibitory efficacy of 80% for BODIPY-GTP and
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60% for BODIPY-GDP binding. Rac1 has been functionally characterized by nonsteroidal anti-inflammatory drug (NSAID), R-Naproxen in the context of ovarian cancer.
R-Naproxen isoform functionally inhibited Rac1 in the cell lines assayed relative to SNaproxen and structurally similar 6-methoxy-2-naphthylacetic Acid (6-MNA). Inhibition
is based on interference with membrane distribution of Rac1 rather than overall protein
levels. Taken together, this study has identified the first competitive GTPase inhibitor
(CID1067700) and also demonstrated the potential utility of the compound for dissecting
GTPase enzymology. The study has also shown that R-Naproxen blocks activation of
Rac1 small GTPase in ovarian cancer cells with implications for the inhibition of ovarian
cancer cell proliferation, migration, and invasion.
Key Words: Rab, Rho, Rac, Cdc42 and Ras GTPases; drug discovery; fluorescent GTP
and GDP; enzyme kinetics; GEF; flow cytometry, ovarian cancer, competitive and
allosteric inhibitors.
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CHAPTER ONE
INTRODUCTION
Overall introduction: Ras superfamily of GTPases

Small GTPases (Ras superfamily) are intracellular, molecular switches that activate
downstream signaling molecules in response to extracellular and intracellular cues. There
are five families: Ras, Rho, Arf/Sar1, Rab, and Ran. Biochemical studies have revealed
many commonalities between small GTPases with respect to synthesis, post-translational
modification, activation, inactivation, and transmission of signals to downstream effector
molecules. Characteristically, small GTPases switch between inactive [guanosine
diphosphate (GDP) bound] and active [guanosine triphosphate (GTP) bound]
conformational states (Fig. 1) (1-4). The conformational switch involves specific
regulatory proteins. While guanine nucleotide exchange factors (GEFs) catalyze release
of bound GDP to allow for GTP binding by small GTPases (5), GTPase activating
proteins (GAPs) on the other hand, facilitate hydrolysis of GTP on the membrane bound
small GTPase proteins.

Conversion between GTP- and GDP-bound states is also associated with transitions
between membrane and cytosolic compartments, respectively (Fig. 1). Translocation of
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the small GTPase to the cytosolic compartment is facilitated by guanine dissociation
inhibitors (GDI-1 or GDI-2), while membrane association is facilitated by Rab escort
protein (REP) immediately after synthesis and prenylation or by GDI during membrane
recycling (Fig. 1) (6). Upon activation, the GTP-bound, membrane associated small
GTPases bind to and transmit signals to multiple effector molecules. Besides regulating
vital cellular processes such as cell signaling, members of Ras superfamily of GTPases
via interdigitated functions of Ras, Rho, Arf/Sar1, Rab, and Ran individual subfamily
members, regulate intracellular trafficking, nuclear translocation and cytoskeletal
rearrangements that occur in response to extracellular signals and cellular needs.
Together the GTPase regulated cascades enable metabolic homeostasis, cell migration,
cell growth and division, cell differentiation and polarization.
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Figure 1. Principal processes governing the regulation of small GTPases. Newly
synthesized small GTPases are modified on C-terminal cysteine residues by lipid
moieties (prenyl or farnesyl chains) to ensure membrane recruitment via REP. GEFs and
GAPs act as small GTPase signal activators and attenuators, respectively. GDI serves to
regulate membrane-cytosol cycling.
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The involvement of small GTPases in diverse human diseases presents the small
GTPases as novel targets for therapeutic intervention hitherto not extensively explored.
Diverse points of small molecule modulation of small GTPase function are possible
ranging from prenylation inhibition to protein-protein interaction regulation (Fig. 1). A
precedent already exists with respect to the use of small molecule inhibitors to prevent
small GTPase membrane recruitment, through inhibition of protein prenylation or
inhibition of regulatory protein interactions (7, 8). Because of the broad cellular
importance of lipid modifications for protein function, the former approach has not
however yielded the selectivity necessary for many applications, though the identification
of more specific prenylation inhibitors remains under active investigation (9-12).

The inhibition of regulatory protein interactions on the other hand holds promise for
being more specific, with the best-characterized example provided by brefeldin A
mediated inhibition of Arf GEF activity (13). Within the Rho-family GEFs, a few
successful attempts have been made to identify inhibitors through screening and rationale
drug design (13-16). It is important to point out that these successes have not been
replicated in any of the members of the Rab family of GTPases whether in terms of
nucleotide binding inhibitors or modulators of protein-protein interactions, in spite of
their cellular importance in cancer and genetic diseases (17, 18).
4

Different strategies can be applied to realize the therapeutic potential of small
GTPases. One strategy is to target the central regulatory properties of small GTPases
based on the switch between GDP and GTP bound states, by finding a small molecule
that can modulate nucleotide binding by the small GTPase. A second strategy is to
identify small molecules that inhibit protein-protein interactions required for GTPase
function. The use of a small molecules is also important to characterize protein function
and has advantages to traditional approaches that rely on dominant negative mutants.
These include, but are not limited to; fast and often-reversible inhibition of protein
function, informative dose–response data, providing room for studying protein of interest
in a multimeric complex without the latter falling apart and availability of small molecule
compounds. All these advantages collectively can lead to a novel endpoint and that is,
providing new insights into mechanistic details of GTPase functions in cellular processes.
In this study, we have sought to assay how small GTPases can be functionally modulated
by small molecules in vitro as well as in a cellular context.

Hypothesis of the dissertation study

Small GTPases are functional targets of small molecules that act as competitive or
allosteric inhibitors.

5

Aims of the study

The central goal of the study was to identify and characterize small molecule inhibitors
of Ras-related GTPases. The stated hypothesis is addressed through two specific aims.
Aim 1 utilizes an in vitro, flow cytometry based assay to distinguish the mechanism of
small molecule action on the Rab7 GTPase. Aim 2 utilizes in vitro and cell based assays
to characterize functional inhibition of the Rac1 GTPase.

Aim1: Mechanism of small molecule Rab7 GTPase inhibition.

The first aim of the study was designed to characterize the mechanism of inhibition of
Rab7 by a sulphur based small molecule; 2-(benzoylcarbamothioylamino)-5,5-dimethyl4,7- dihydrothieno[2,3-c]pyran-3-carboxylic acid (CID 1067700; PubChem
CID1067700). CID1067700 was identified at the University of New Mexico Center for
Molecular Discovery (UNMCMD) by screening the NIH Roadmap library of over
300,000 compounds (Pubchem AID 1333, 1334, 1340). To address the first aim, a bead
based flow cytometry approach was used (Fig. 2), where gluthione-S-transferase (GST)
tagged Rab7 was mobilized on a glutathione bead and then the effect of CID1067700
assayed in terms of loss of BODIPY-GTP or -GDP binding by Rab7. The approach
enables distinction of allosteric or competitive inhibition of nucleotide binding (Fig. 2).
6

Using the bead based approach; the effect of CID1067700 on Rab7 was assayed in dose
dependent binding assays and kinetic measurements of nucleotide binding and
dissociation. Structure activity relationships of several chemical analogs of CID1067700
were also tested to establish essential features for small molecule inhibition.
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Figure 2: Design of glutathione bead based high throughput screening (HTS) to
identify small GTPase activators and inhibitors. GST-tagged small GTPase is
immobilized on a gluthathione bead of definite mean diameter (13 µm). The effect of the
small molecule on the fluorescent nucleotide binding by the GTPase is then assayed
using flow cytometry. Competitive inhibitor binds the same site as the nucleotide while
allosteric modulator (activator or inhibitor) binds the indicated site (typically GTPase
switch region) outside the nucleotide binding pocket. The read out of the assay is mean
channel fluorescence.
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Aim 2: In vitro and cell based assays to study functional inhibition of Rac1 GTPase

The second aim was centered on the small molecule inhibition of the Rac1 GTPase.
Functional modulation of Rac1 small GTPase by the non-steroidal anti-inflammatory
drug (NSAID), R-Naproxen was assessed in the context of ovarian cancer cells. RNaproxen was identified the University of New Mexico Center for Molecular Discovery
(UNMCMD) by screening a Prestwick chemical library of off-patent molecules. The
effects of R-Naproxen on Rac1 activation status, Tiam1 GEF interaction, membrane
distribution and overall Rac1 protein levels were measured.

Biological and chemical connection between Rab7 and Rac1

In terms of function, the Rab5, Rab7 and Rac1 GTPases are intimately linked to enable
coordination between molecular trafficking and actin cytoskeletal remodeling,
respectively (Fig. 3). It has been shown that Rac1 interaction with endosomes is
dependent on Rab5 GTPase and that the Rab5-Rac1 circuitry is significant in the role of
Rac1 in modulating cell motility (19, 20). This is supported by evidence showing that,
ectopic expression of Rab5 in HeLa cells increases early endosomal accumulation of
active Rac1 and Tiam1 GEF as well as induction both lamellipodia and circular dorsal
ruffles (19). Since Rab5-Rab7 conversion is an important regulatory process in cargo
9

trafficking as will be explained later, one can speculate that it may also be involved in
Rab5 mediated Rac1 trafficking. Also, Armus which is a Rac1 effector (21, 22), is
reported to inactivate Rab7 by facilitating nucleotide hydrolysis again suggesting a cross
talk between Rab7 and Rac1 in trafficking and regulation of actin assembly. The
composite data emphasize that the cellular role of Rac1 cannot be divorced from the
endocytic trafficking pathway. We can also emphasize a common denominator with
respect to chemical connection between Rab7 and Rac1. The current study is about
CID1067700 and R-Naproxen small molecules capable of functionally impacting Rab7
and Rac1 respectively. CID1067700 which competitively inhibits nucleotide binding by
Rab7, may also inhibit Rac1 by binding the nucleotide binding site since among the Ras
family of GTPases, the principal amino acid residues of the nucleotide binding site are
evolutionarily conserved. The potency of inhibition may however vary due to differences
in the orientation of the nucleotide pocket between the two GTPases. R-Naproxen in this
study displays characteristics typical of allosteric inhibitor. Thus, its ability to inhibit
Rac1 may not be replicated in Rab7 due to differences in amino acid residues on its
binding site between the two GTPases and also the ensuing potential differences in the
protein conformation which may be caused by its binding. Thus, within the broader
context of biological and chemical connection, both Rab7 and Rac1 are functionally
10

interdependent and may be modulated in a similar way by a small molecule that displays
competitive characteristics.
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Figure 3: Roles of Rab7 and Rac1 small GTPases in molecular trafficking and actin
remodeling. GDP bound Rac1 is localized at early endosomal membranes where it
interacts with Tiam1 GEF, converting the protein to the active GTP bound state. Active
Rac1 interacts with PAK1 effector at the plasma membrane and induces actin
remodeling. Rab7 is transiently localized to early endosomes where it facilitates Rab5Rab7 conversion and transport of cargo to late endosomes. Rab7 is important in the
regulation of antigen processing, growth factor sequestration and lysosomal degradation,
among other functions.
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CHAPTER TWO
CHARACTERIZATION OF RAB7 SMALL GTPASE WITH CID1067700
Abstract

Rab7 plays a significant role in late endocytic events of mammalian cells that serve to
regulate growth factor downregulation, pathogen degradation, autophagy, among other
events central to normal cell physiology. Here we report on the small chemical molecule
2-(benzoylcarbamothioylamino)-5,5-dimethyl-4,7- dihydrothieno[2,3-c]pyran-3carboxylic acid (CID 1067700; PubChem CID1067700) as an inhibitor of nucleotide
binding by Rab7 and possibly other Ras-related GTPases. The mechanism of action of
this pan-GTPase inhibitor has been characterized in the context of the Rab7 GTPase as
there are no known inhibitors of Rab GTPases. Bead-based flow cytometry was used to
establish that CID1067700 had significant inhibitory potency on Rab7 nucleotide binding
with a respective inhibitory efficacy of 80% for BODIPY-GTP and 60% for BODIPYGDP binding. The compound behaves like a competitive inhibitor of Rab7 nucleotide
binding based on both equilibrium binding and kinetic assays. Molecular docking
analyses are compatible with CID1067700 fitting into the nucleotide binding pocket of
the GTP-conformer of Rab7. Structural features pertinent to CID1067700 inhibitory
activity have been identified through an initial structure activity analyses. These studies
13

identified a molecular scaffold that may serve in the generation of more selective probes
for Rab7 and other GTPases. Using effector protein interaction, we have also shown that
when CID1067700 is bound to the nucleotide binding site, Rab7 does not adapt
conformational state analogous to GTP bound (active) state. Taken together, this study
has identified the first competitive GTPase inhibitor and demonstrated the potential
utility of the compound for dissecting the enzymology of the Rab7 GTPase as well as
serving as a model for other small molecular weight GTPase inhibitors.

Introduction

The founding Rab GTPase family members were identified in secretion deficient yeast
mutants and in mammalian brain, thereby revealing their essential roles in the regulation
of membrane trafficking (23-25). The human genome encodes more than 70 Rab
GTPases and Rab-like proteins (26-28). Still only a fraction of these Rab GTPases have
been studied in significant detail. Currently there are ~25 Rab GTPases with
characterized functions in endoctyosis and related processes (Appendix A) and (29).
Rab7 is one of the most studied endocytic Rab GTPases due to its pivotal roles in
shunting molecules for recycling through the Golgi, back to the plasma membrane or to
degradation (Fig. 4).
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Figure 4: Intracellular trafficking pathways associated with Rab7. Rab7 regulates
cargo trafficking to the lysosomes for degradation via late endosomes, cargo recycling
through the Golgi back to the plasma membrane, autophagy, phagolysosome fusion and
osteoclast-mediated bone resorption.
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Functional role of Rab7

Rab7 plays a significant role in endocytic trafficking and other degradative pathways
such as autophagy and phagocytosis (27, 29, 30). Rab7 regulated pathways are important
for normal cell physiology as illustrated by the following examples. Firstly, Rab7 and its
effectors are central to the regulation of growth factor signaling and receptor down
regulation through lysosomal degradation (31-33). Increased receptor downregulation
may be pertinent to reducing hyperactive signaling in cancers where expression of
epidermal growth factor receptor is elevated and/or constitutively active, where Rab7 is
also overexpressed (34, 35). Upregulation of active Rab7 may lead to modest increases in
growth factor receptor degradation.

Secondly, Rab7 participates in phagocytic and autophagic processes. Rab7 facilitates
the fusion of autophagosomes with lysosomes that is important in nutrient regulation,
clearance of cytoplasmic protein aggregates and degradation of organelles (36-42).
Imbalances in autophagy are associated with immune dysregulation, cancer, and
neurodegeneration (43, 44). Extracellular pathogens and dead cells engulfed into
phagosomes are known to be cleared through a maturation phase requiring phagosome
fusion with endosomes (45, 46). The maturation process is characterized by formation of

16

a late phagosome and a subsequent phagolysosome, thus degradation of pathogens and
cellular debris are dependent on Rab7 (47, 48).

Thirdly, Rab7 is important for the biogenesis of secretory lysosomes such as
melanosomes and lytic granules secreted by immune cells that are important in normal
pigmentation and immune cell function. Rab7 has been shown to associate with early
and intermediate stage melanosomes during melanosomal transport (49-51). This was
further illustrated in human amelanotic melanoma cells (SK-mel-24) where expression of
dominant negative Rab7 impaired vesicular transport of tyrosinase and TRP-1 proteins
from the trans-Golgi network to maturing melanosomes (52), and also in MMAc
melanoma cells, where the GTP-bound (active) form of Rab7 promoted melanogenesis
by regulating gp100 maturation (51). Secretory lysosome exocytosis also accompanies
bone remodeling events during which formation of a ruffled border facilitated by Rac1 is
accompanied by transport and fusion of acidic intracellular vesicles with the plasma
membrane in a Rab7 regulated process (53-55). Improper transport of melanosomal and
lytic substances can potentially be cytotoxic to cells coupled with defects in
pigmentation, poor immune system regulation and bone defects. This therefore
emphasizes the important role Rab7 is playing in secretory lysosome biogenesis and
function.
17

Fourthly, Rab7 is important for the regulation of lipid homeostasis and lipid signaling
in the control of vesicle trafficking. Proper sphingolipid (SLs) transport and metabolism
is important for membrane structure, cell signaling, regulation of cell growth and the cell
cycle and when aberrant leads to sphingolipid storage disorders that cause mental
retardation and premature death (56-58). Nieman-Pick type C (NPC) disease is
characterized the accumulation of sphingolipids in late endosomes and lysosomes in
tissues such as liver, spleen and brain (59, 60). The defects in cholesterol and
sphingolipid storage are dramatically improved by the overexpression of Rab7, which
enhances intracellular trafficking of cholesterol and sphingolipids (61). Rab7 together
with the lipid kinase hVps34/hVps15 (62) and the myotubularin lipid phosphatases
(MTM1 and MTMR2) serves as a molecular switch controlling the sequential synthesis
and degradation of endosomal PI(3)P important for the spatial and temporal regulation of
vesicle budding and fusion (63, 64). Lipid homeostasis also involves the function of
ORP1L which is a Rab7 effector. In Mel JuSo cells cells, ORPIL was shown to act as a
sensor of cholesterol accumulation in late endosomes in addition to transmitting
information to the Rab7–RILP–p150 glued complex through the formation of
endoplasmic reticulum– late endosome membrane contact sites (65). Normal cellular
lipid levels dictate processes ranging from vesicular trafficking, signaling to receptor
18

degradation among others, defects in which may result in human disease. These confirm
the importance of Rab7 in lipid synthesis and trafficking.

Fifthly, Rab7 is important in regulating cell-cell adhesion. Cell differentiation is
characterized by epithelial cells undergoing epithelial–mesenchymal transition (66). This
change is marked by down-regulation and intracellular sequestration of E-cadherin and
other cell-cell junction proteins that are later trafficked via the endocytic pathway to the
lysosomes (66). Enhanced transport of ubiquitinated E-cadherin to the lysosomes occurs
through hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) and v-Srcinduced activation of Rab7 mediated transport, thereby contributing to the regulation of
cell-cell adhesion (67).

The enumerated Rab7 functions in endocytic membrane transport occur in different
cellular contexts yet overall serve to regulate key cellular functions that dictate cell
viability and differentiation. All Rab7 functions depend on coordinated spatial and
temporal interactions between Rab7 and other regulatory partner molecules as discussed
further in the following section.

19

Rab7 and its accessory effector molecules

Membrane trafficking requires a series of discrete temporally and spatially regulated
steps that include: 1) cargo selection and clustering, 2) vesicle coat protein recruitment,
vesicle budding through the action of membrane curvature inducing proteins, 3)
cytoskeleton mediated translocation, and 4) docking and fusion with the target
membrane. Rab GTPases are known to function in all aspects of transport through the
sequential interaction with different effectors. Rab7 interacts with multiple effector
molecules to regulate endocytic transport, including proteins regulating phosphoinositide
signaling, motor proteins controlling bidirectional cytoskeletal transport, proteasome
subunits controlling degradation, among others (62, 63, 68-71) (Appendix B).

One of the best characterized Rab7 effector proteins is the Rab7 interacting lysosomal
protein (RILP) which is important for cargo sorting and retrograde cytoskeletal
translocation. Upon RILP recruitment to late endosomes and lysosomes binds and
prolongs the Rab7 activation (GTP bound state) (68, 72-76). A complex of Rab7 and
RILP induces recruitment of dynein-dynactin motor complexes to Rab7-containing late
endosomes and lysosomes (69, 77, 78). RILP in turn mediates the membrane recruitment
of VPS22 and VPS36 of the ESCRT-II machinery, which is responsible for
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multivesicular body formation through intraluminal vesicle invagination and important in
exosome formation and growth factor receptor sorting (31, 79). Depletion of RILP leads
to elevated levels of four late endosomal molecules (lysobisphosphatidic acid, Lamp1,
CD63 and cation-independent mannose-6-phosphate receptors) besides inhibiting ligandmediated degradation of epidermal growth factor receptors [EGFRs] (31). Thus, Rab7
together with RILP controls late endosomal sorting of lipids and proteins associated with
cargo delivery. RILP has been shown to function in concert with ORP1L effector
whereby, a complex involving RILP, Rab7, p150Glued and ORP1L activates microtubule
(dynein) motors and initiates translocation of late endosomes on microtubules (80) to
facilitate vesicular transport to lysosomes.

The ubiquitin–proteasome pathway is a well-known mechanism for the targeted
degradation of cytosolic proteins (81, 82). The proteasome mediated by the α-subunit
XAPC7 (also known as PSMA7, RC6-1, and HSPC) has been shown to interact
specifically with Rab7 that aids in its recruitment to the membranes of multivesicular late
endosomes (71, 82). The XAPC7 interaction facilitates the connection between cargo
sorting and degradative events.
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Rabring7 (Rab7-interacting ring finger protein) originally isolated using a CytoTrap
system (83), is also a downstream effector protein of Rab7 involved in EGFR trafficking
for lysosomal degradation through its E3 ligase activity. Overexpression of Rabring7 was
shown to alter EGFR degradation besides inducing perinuclear aggregation of lysosomes
(84, 85). High cellular levels of Rabring7 are also marked by enhanced accumulation of
the acidotropic probe LysoTracker (83), a phenomenon which implicates Rabring7
protein in lysosome biogenesis and receptor degradation. Internalization of
polyubiquitylated TrkA involves its interaction with Unc51.1 and p62, the atypical
protein kinase C interacting protein and this degradative process is also thought to
involve the Rabring7 effector.

Rab7 interacts with hVps34 kinase, its adaptor protein p150 and phosphatidylinositol
3-kinase (18, 27, 63). The complex ensures regulated phosphatidylinositol 3-phosphate
synthesis on early and late endosomes (62). Phosphatidylinositol 3-phosphate enriched
membrane domains facilitate membrane fusion through the recruitment of FYVE domain
containing proteins, and intraluminal vesicle sequestration of growth factors (86).
Myotubularin phosphatase mediated degradation of phosphatidylinositol 3-phosphate
terminates the signal and is accompanied by a requisite dissociation of the Rab7/Vps34
complex (64).
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As illustrated by the given examples, coordinate interactions between Rab7 and
multiple effector proteins cut across key processes that are crucial to cell function.
Misregulation leads to various disease states such as cancer, neurodegenerative disease
and cell infection by pathogens. Collectively, the data implicate Rab7 as an important
small molecule target.

Regulation of Rab7

The principal processes pertinent to regulation of Rab7 include prenylation and
membrane insertion, nucleotide binding and hydrolysis, and effector protein interaction
(Fig. 1) (28, 87). The function of Rab GTPases are primarily dictated by both proper
membrane association and a nucleotide exchange mechanism that turns the protein on
through GTP binding and off through GTP hydrolysis based on nucleotide dependent
conformational changes. In mammalian cells, Rab7 can localize to late endosomes,
lysosomes, cytosol, phagosomes, melanosomes and exosomes (27, 30, 37, 39, 52, 88, 89).
Location of Rab7 at these sites depends on whether the GTPase is in the ‘active’ or
‘inactive’ state. After translation, cytosolic GDP bound Rab7 undergoes posttranslational geranylgeranylation which enables it to associate reversibly with
intracellular membranes and thus is critical to its biological function (90-97).
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The process of Rab7 geranylgeranylation proceeds in a sequential manner. Newly
synthesized Rab7 protein first associates with Rab escort protein (REP-1) via its alphasubunit (98). Rab7 then interacts with the Rab binding platform of REP-1 via an extended
interface involving the Switch 1 and 2 regions of Rab7 with the C terminus of the REP-1
molecule functioning as a mobile lid covering a conserved hydrophobic patch of REP-1
(99). The integrity of this interaction is significant since mutations in the REP-1 gene in
humans have been associated with X-chromosome-linked defect, choroideremia, a
progressive disease that inevitably culminates in complete blindness (99-102).

Once bound to Rab7, REP-1 presents the GTPase to the Rab geranylgeranyl
transferase (RabGGTase) enzyme loaded with the isoprenoid donor geranylgeranyl
pyrophosphate, GGpp (103). The enzyme then catalyzes covalent modification of the Rab
protein at the C-terminal cysteine motifs with two geranylgeranyl (GG) moieties (98,
104). The highly variable C-terminal domain of Rab7 contains two cysteine residues that
are subject to prenylation (97, 105). The addition of lipid moieties on Rab7 is similar for
all Rab proteins and is crucial for membrane recruitment (90-94).

Rab7 delivery to the target membrane involves release of GDI. This is accomplished
by a membrane associated protein factor called GDI-displacement factor (GDF) (106).
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GDFs are present either in the early secretory pathway or within the endocytic pathway
(94). The current model has it that once delivered to the membrane and GDI extracted by
GDF, Rab7 diffuses within the plane of the membrane and is then stabilized by relevant
effector binding (107). This model still needs to be refined since there are studies
suggesting that the necessity of GDF to extract GDI may not be thermodynamically
tenable (96). Delivered GDP bound Rab7 can then undergo nucleotide exchange by
losing its GDP for GTP in order to perform downstream functions. Following GEF
catalyzed activation, Rab7 GTPase interacts in a temporally and spatially regulated
manner with specific effector molecules (Appendix B). These include sorting adaptors,
tethering factors, kinases, phosphatases and motor proteins that ensure cargo sorting,
vesicle transport and fusion (2). Unlike Rab5 with a known GEF as Rabex5, the Rab7
GEF is still under investigation. Ccz1-Mon1 acts as the yeast Ypt7 GEF(108), an
orthologue of mammalian Rab7. Termination of Rab7 GTPase activation is achieved by
intrinsic GTPase hydrolysis and GAP stimulated catalysis (109). Currently, some TBC
domain containing proteins such as TBC1D5 and TBC1D15 have been identified as Rab7
GAP (21, 109, 110).

Another regulatory mechanism with significant control on Rab7 activity is Rab5-Rab7
conversion (Fig. 3). Conversion is thought to confer directionality to the membrane
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trafficking events leading to membrane maturation (111-116). It involves HOPS complex
mediated recruitment of Rab7 into Rab5 positive organelles (112, 113). There are
suggestions that hVps39 may also be involved in this process as part of the complex (108,
114, 115).

Association of the Rab7 GTPase with human disease

Rab7 has been associated with different types of diseases ranging from those due to
mutations in the Rab7 encoding gene to others that may result from manipulation of the
transport role of Rab7 by pathogens (117). Diseases associated with Rab7 arising from
genetic mutations tend to be primarily peripheral neuropathies. The latter can be caused
by mutations in multiple genes required for axon viability or Schwann cell dependent
myelination (118, 119). Charcot-Marie-Tooth type 2B (CMT2B) disease (also known as
hereditary sensory neuropathy 1C) causes axonal degeneration and has been linked to
four missense mutations in Rab7 gene (29, 33, 120-122). The mutations target highly
conserved residues that reside on the surface of Rab7 and affect nucleotide exchange (33,
123-125). In neuronal N2A and PC12 cell lines, expression of the mutant proteins
inhibits neurite outgrowth (126). Such changes in neuronal differentiation are likely due
to prolonged phosphorylation of the TrkA receptor and altered Erk nuclear signaling
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caused by the expression of the mutant Rab7 proteins (33). Patients with CMT2B disease
usually manifest severe sensory loss, distal muscle weakness and a high frequency of foot
ulcers and infections with frequent digit amputations (127, 128). Because CMT2B is an
autosomal dominant disease, it is predictable that selective inhibition of the mutant
protein or enhancement of wild-type Rab7 activity might be beneficial therapeutic
interventions.

With respect to the usual Rab7 role, CMT2B mutant proteins may potentially alter
Rab5-Rab7 conversion, Rab7-effector protein interactions and therefore impact Rab7regulated trafficking to and from the cell body that are required for maintenance of axon
viability and normal impulse transmission. For example the CORVET and HOPS protein
complexes identified in yeast and conserved in mammalian systems are thought to enable
transition of cargo from early to late endosomes and lysosomes (129). GTP-bound Rab7
recruits the dynein/dynactin motor complex through the Rab interacting lysosomal
protein (RILP) and in conjunction with Rabring7 promotes growth factor degradation
(68, 83, 85).
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Taken together, the enumerated roles of Rab7 in addition to its regulation and effector
protein interactions coupled with its overexpression in cancer and mutant Rab7
associated with peripheral neuropathies, make Rab7 an important candidate for small
molecule modulation. Such molecules could have utility both for dissecting the
mechanistic details of processes governed by Rab7, as well as for the future development
of targeted therapies (18, 130). This by extension may provide a platform for small
molecule modulation of other members of the Rab family, a growing number of which
are implicated in diseases ranging from pigmentation and bleeding disorders to bone
diseases and thereby address questions that remain regarding ubiquitous and cell type
specific functions of Rab GTPases and how these may contribute to disease pathogenesis.
More so, this approach may provide detailed understanding of how Rab GTPases
coordinate with regulatory proteins, downstream effector proteins and other GTPases to
effect cargo selection, vesicle formation, translocation through cytoskeletal networks, and
targeted vesicle fusion (131, 132). Thus, we sought to investigate how Rab7 function may
be modulated by a small molecule both in the context of understanding normal Rab7
function as well as in terms of characterizing Rab7 as a potential therapeutic target. This
is a new area that has not been investigated despite the important cellular functions and
disease pathologies associated with Rab7. For this purpose, I used a sulfur based small
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chemical molecule herein called; 2-(benzoylcarbamothioylamino)-5,5-dimethyl-4,7dihydrothieno[2,3-c]pyran-3-carboxylic acid (Pubchem #: CID1067700).

Materials and Methods

Reagents

Reagents used in this study were obtained from Sigma unless otherwise indicated.
Sephadex G-25, glutathione (GSH) Sepharose 4B, and Superdex peptide beads (13 µm
with an exclusion limit of 7 kDa) were from Amersham Biosciences. BODIPY (4,4difluoro-4-bora-3a,4a-diaza-s-indacene or dipyrromethene boron difluoride) nucleotide
analogues (BODIPY FL GTP 2’-(or 3’)-O-[N-(2-aminoethyl)urethane] G-35778 and
BODIPY FL GDP 2’-(or-3’)-O-[N-(2-aminoethyl)urethane], G-22360) were from
Invitrogen Molecular Probes (Carlsbad, CA, USA). Concentrations of BODIPY
nucleotides were based on absorbance measurements and an extinction coefficient value
of 80,000 M-1 cm-1. 2-(benzoylcarbamothioylamino)-5,5-dimethyl-4,7dihydrothieno[2,3-c]pyran-3-carboxylic acid with compound identification number
(CID1067700) was from ChemDiv.
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Expression and purification of GST-Rab7

GST–Rab7 protein was expressed in E. coli BL21 (DE3). Cultures were grown at 37°C
to a bacterial density of 0.5-0.7 absorbance units at 595 nm and protein induced by
transfer to room temperature and addition of 0.2 mM isopropyl-beta-D-1thiogalactopyranoside (IPTG) for 16-18 h to maximize yield of properly folded active
fusion protein. Purification of GST-Rab7 was performed according to standard
procedures and as previously described (133).

Synthesis of glutathione beads for flow cytometry assay

High GSH density beads used for flow cytometry were synthesized by loading
Superdex peptide beads with GSH as previously reported (133, 134).

Immobilization of Rab7 on GSH beads for flow cytometry

All nucleotide binding to Rab7 and measurements were performed in the HPS buffer
(30 mM Hepes, pH 7.5, 20 mM NaCl and 100 mM KCl) containing 1 mM EDTA. A
BectonDickinson FACScan flow cytometer with a 488-nm excitation laser and standard
detection optics was used for all assays (133). Pure GST-Rab7 protein was incubated in
96-well plates at 4°C overnight with 105 GSH beads in a total volume of 100 µl of HPS
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buffer containing 1 mM EDTA and 1 mM dithiothreitol (DTT) added fresh. Unbound
protein was removed by centrifugation washes by spinning GST-Rab7 bound to GSH
beads twice at 800 g followed by resuspension of washed protein in fresh HPS buffer
containing 1 mM EDTA and 1 mM dithiothreitol (DTT).

Dose response or competition binding assays

Dose response assays were conducted in two different modes. In the first case, 5x103
GSH beads loaded with GST-Rab7 were incubated with a fixed concentration of
nucleotide (GDP or GTP) for 1 h in the presence of 1% DMSO (final) or increasing
concentrations of CID1067700 (10-3 – 100 µM) in 1% DMSO and a total volume of 20 µl
on a 96-well plate. A stock solution of CID1067700 (10 mM) was prepared in 100%
DMSO and stored in single use aliquots at -80°C. In the second mode, 5x103 GSH beads
loaded with GST-Rab7 protein were incubated for 2 h 15 min at 4 °C with varying
concentrations of fluorescent guanine nucleotide (0–2 µM) in a total volume of 20 µl on a
96-well plate in the presence of either 1 % DMSO or a fixed CID1067700 concentration
(0.1 – 1µM). For measurements on the flow cytometer, samples were transferred to a
falcon tube (BD Bioscience) for flow cytometry and were diluted at least 10-fold in HPS
buffer. This dilution step was necessary to ensure discrimination of bead-associated
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fluorescence and background fluorescence of soluble proteins and also ensured sufficient
sample volume for the measurement.

Nucleotide dissociation assays in the presence of CID1067700
Nucleotide dissociation under equilibrium conditions was accomplished by first
incubating 1.5x105 GSH bead bound GST-Rab7 with fixed BODIPY-GTP (100 nM) or
BODIPY-GDP (40 nM) for 2hr 15 min at 4 oC followed by initiating release of bound
nucleotide with either unlabeled GDP (10 µM) or CID1067700 (10 µM). As a negative
control, GST-Rab7 was preloaded with unlabelled GDP (1 mM) for 2hr 15 min at 4oC
prior to adding BODIPY-GTP or BODIPY–GDP at the above concentrations for a further
2hr 15 min and then similarly initiating release of bound BODIPY-linked nucleotide with
unlabeled GDP (10 µM) to obtain fluorescence for non-specific binding under
equilibrium binding conditions. This low level bead associated fluorescence was
subtracted from specific binding to obtain accurate measurement of the off rates.
Molecular docking of CID1067700 on Rab7
Docking calculations were performed using OpenEye Fred (Fred, version 2.2.5,
OpenEye Scientific Software, Inc., Santa Fe, NM, USA, www.eyesopen.com, 2010)
docking software. Rab7 crystal structures (PDB code: 1T91 GDP-conformer, 1VG8
GNP-conformer) were used to dock CID1067700 on Rab7 for the wild type. Chemgauss3
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scoring function was used to evaluate ligand binging potential. Docking simulations
provide only a qualitative assessment of binding probability of our ligand to Rab7 and
should be examined with care, however the results indicate that CID1067700 can
potentially bind to Rab7 nucleotide binding site and no steric constrains were observed
Data analyses
All data processing and analyses employed GraphPad Prism software (GraphPad
Software, San Diego). For kinetic experiments, raw data acquired were first processed
using IDLE query software (obtained from University of New Mexico Center for
Molecular Discovery, UNM CMD) before further analysis using GraphPad Prism. All
experiments are representative of at least three independent trials.
Synthesis of CID1067700 derivatives for structure activity analyses
Structure activity relationship (SAR) was performed to understand the relationship
between the chemical structure of CID1067700 and its activity. A lot of times, the
activity of a small molecule can be a pharmacological response, binding, toxicity or any
other quantifiable event. In our context, the activity of interest was pharmacological
response marked by modulation of nucleotide binding by Rab7 by CID1067700.
Derivatives of CID1067700 were synthesized and analyzed for purity by collaborating
laboratory at University of Kansas. The steps involved were carried out using standard
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chemical synthesis protocol. Below is a sequential summary of the methods employed.

Chemistry and analytical details
1

H and 13C NMR spectra were recorded on a Bruker AM 400 spectrometer (operating

at 400 and 101 MHz respectively) in CDCl3 with 0.03% TMS as an internal standard or
DMSO-d6. The chemical shifts (d) reported are given in parts per million (ppm) and the
coupling constants (J) are in Hertz (Hz). The spin multiplicities are reported as s =
singlet, br. s = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublet
and multiplet. The LCMS analysis was performed on an Agilent 1200 RRL
chromatograph with photodiode array UV detection and an Agilent 6224 TOF mass
spectrometer. The chromatographic method utilized the following parameters: a Waters
Acquity BEH C-18 2.1 x 50 mm, 1.7 um column; UV detection wavelength = 214 nm;
flow rate = 0.4 ml/min; gradient = 5 - 100% acetonitrile over 3 minutes with a hold of 0.8
minutes at 100% acetonitrile; the aqueous mobile phase contained 0.15% ammonium
hydroxide (v/v). The mass spectrometer utilized the following parameters: an Agilent
multimode source which simultaneously acquires ESI+/APCI+; a reference mass solution
consisting of purine and hexakis (1H, 1H, 3H-tetrafluoropropoxy) phosphazine; and a
make-up solvent of 90:10:0.1 MeOH:Water:Formic Acid which was introduced to the LC
flow prior to the source to assist ionization. Melting points were determined on a
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Stanford Research Systems OptiMelt apparatus. Synthesized analogs were prepared by
the general route depicted in Fig. 5. Stepwise procedures for all synthesized analogs and
intermediates are described. Analytical characterization is provided for all tested
commercial and synthetic compounds itemized in this section.
Figure 5. General scheme used for synthetic analogs

tert-Butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate. Following a
previously reported procedure. Tetrahydro-4H-pyran-4-one (0.28 mL, 3.0 mmol, 1
equiv.), tert-butyl cyanoacetate (0.47 mL, 3.3 mmol, 1.1 equiv.), sulfur (0.106 g, 3.30
mmol, 1.1 equiv.), and morpholine (0.39 mL, 4.5 mmol, 1.5 equiv.) were dissolved in
EtOH (9 mL) and stirred at 50 oC1 for 16 h. The solvent was removed and water (7 mL)
was added. The product was extracted with EtOAc (2 × 7 mL) and purified by
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preparatory HPLC (0-20% EtOAC:hexanes). The product was isolated as a clear, pale
yellow oil (0.77 g, quantitative yield). 1H NMR (400 MHz, CDCl3) δ 5.98 (s, 2H), 4.55 (t,
J = 2.0 Hz, 2H), 3.90 (t, J = 5.6 Hz, 2H), 2.79 (ddd, J = 7.6, 3.8, 2.0 Hz, 2H), 1.54 (s,
9H). 13C NMR (101 MHz, CDCl3) δ 165.38, 161.65, 130.33, 114.60, 106.76, 80.37,
65.20, 64.66, 28.57, 27.94.

tert-Butyl 2-(3-benzoylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylate. tert-Butyl 2-amino-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate
(0.099 g, 0.39 mmol, 1 equiv.) and PhCONCS (0.06 mL, 0.4 mmol, 1 equiv.) were
dissolved in THF (2 mL) and stirred at 50 oC for 16 h. The solvent was removed and the
product was purified by preparatory HPLC (0-30% EtOAC:hexanes). The product was
isolated as a white solid (0.131 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ 14.75 (s,
1H), 9.21 (s, 1H), 7.92 (dd, J = 5.2, 3.3 Hz, 2H), 7.64 – 7.57 (m, 1H), 7.54 – 7.46 (m,
2H), 4.71 (s, 2H), 3.94 (t, J = 5.6 Hz, 2H), 2.90 (t, J = 5.6 Hz, 2H), 1.63 (s, 9H). 13C
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NMR (101 MHz, CDCl3) δ 173.72, 165.23, 164.54, 147.15, 133.48, 131.81, 129.36,
129.04, 127.77, 125.77, 117.76, 82.36, 65.20, 64.71, 28.51, 27.38.

2-(3-benzoylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid
(SID 99381129, CID 46916266). To a solution of tert-Butyl 2-(3-benzoylthioureido)-5,7dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (0.104 g, 0.25 mmol, 1 equiv.) in DCM (10
mL) was added TFA (2 mL, 26 mmol, 100 equiv.), and the reaction was stirred at rt for
16 h. The solvent was removed and the product was triturated with 1:1 Et2O/hexanes (25
mL) and filtered. The product was purified by mass-directed reverse-phase
chromatography and isolated as a white solid (3 mg, 3% yield). 1H NMR (400 MHz,
CDCl3) δ 14.92 (br s, 1H), 9.02-9.09 (m, 1H), 7.83-7.91 (m, 1H), 7.55-7.66 (m, 2H),
7.41-7.50 (m, 2H), 7.19-7.23 (m, 1H), 4.69-4.76 (m, 2H), 3.92-3.98 (m, 2H), 2.88-3.03
(m, 2H). LCMS retention time: 2.955 min; LCMS purity at 215 nm = 100%. HRMS m/z
calculated for C16H15N2O4S2 [M++1]: 363.0468, found 363.0464.
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tert-Butyl 2-amino-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate.
A mixture of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (0.300 g, 2.34 mmol, 1 eq), tertbutyl cyanoacetate (0.37 mL, 2.57 mmol, 1.1 eq), sulfur (0.083 g, 2.57 mmol, 1.1 eq),
morpholine (0.30 mL, 3.51 mmol, 1.5 eq), and ethanol (7 mL) was heated at 50 °C for 16
h. The reaction mixture was then filtered, and the filter cake washed with ethyl acetate
(20 mL). Purification by silica gel chromatography (0-20% EtOAc:Hex ramp over 20
min) afforded the desired product tert-butyl 2-amino-5,5-dimethyl-5,7-dihydro-4Hthieno[2,3-c]pyran-3-carboxylate as a yellow solid (0.631 g, 2.23 mmol, 95 % yield). 1H
NMR (400 MHz, CDCl3) δ 5.88 (s, 2H), 4.52 (t, J = 1.9, 2H), 2.64 (t, J = 1.9, 2H), 1.53
(s, 9H), 1.26 (s, 6H).
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tert-Butyl 2-(3-benzoylureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylate. tert-Butyl 2-amino-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylate (0.116 g, 0.41 mmol, 1 equiv.) and PhCONCO (0.06 mL, 0.5 mmol, 1.2
equiv.) were dissolved in THF (2 mL) and stirred at 50 oC for 16 h. The solvent was
removed and the product was purified by preparatory HPLC (0-40% EtOAC:hexanes).
The product was isolated as a white solid (0.105 g, 59% yield). 1H NMR (400 MHz,
CDCl3) δ 13.26 (s, 1H), 9.81 (s, 1H), 8.13 (d, J = 7.0 Hz, 2H), 7.65 (d, J = 6.7 Hz, 3H),
4.72 (s, 2H), 2.75 (s, 2H), 1.64 (s, 9H), 1.32 (s, 6H).

2-(3-Benzoylureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic
acid (SID 99381130, CID 46916265). To a solution of tert-butyl 2-(3-benzoylureido)5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (0.105 g, 0.24 mmol, 1
equiv.) in DCM (10 mL) was added TFA (0.5 mL, 6.5 mmol, 27 equiv.), and the reaction
was stirred at rt for 5 days. The solvent was removed under reduced pressure and the
product was purified by preparatory HPLC (0-5% MeOH/DCM), followed by mass39

directed reverse-phase chromatography and isolated as a white solid (6 mg, 7% yield). 1H
NMR (400 MHz, DMSO) δ 13.11 (s, 1H), 11.39 (s, 1H), 8.05 – 7.99 (m, 2H), 7.69 – 7.63
(m, 1H), 7.55 (t, J = 7.7 Hz, 2H), 4.62 (s, 2H), 2.71 (s, 2H), 1.22 (s, 6H). LCMS retention
time: 2.872 min; LCMS purity at 215 nm = 100%. HRMS m/z calculated for
C18H19N2O5S [M++1]: 375.1009, found 375.1013.

5,5-dimethyl-2-(2-phenylacetamido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylic acid (SID 99381117, CID 740871). 5,5-Dimethyl-2-(2-phenylacetamido)5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid was purchased from ChemBridge
(CAS 303966-15-6) and purified by mass-directed reverse-phase chromatography and
isolated as a white solid (3 mg, 100% purity). 1H NMR (400 MHz, CDCl3) δ 10.88 (s,
1H), 7.43 – 7.37 (m, 2H), 7.33 (dd, J = 6.7, 4.3 Hz, 3H), 4.72 (s, 2H), 3.85 (s, 2H), 2.85
(s, 2H), 1.35 (s, 6H). LCMS retention time: 3.045 min; LCMS purity at 215 nm = 100%.
HRMS m/z calculated for C18H20NO4S [M++1]: 346.1108, found 346.1110.

40

Methyl 2-(3-benzoylthioureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylate (SID 99381118, CID 1251121). To a combined mixture of methyl 2-amino5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (ChemBridge, CAS
713111-73-0, 31 mg, 0.13 mmol, 1 equiv.) and PhCONCS (0.02 mL, 0.15 mmol, 1.2
equiv.) was added THF (0.7 mL). The resulting solution was stirred at 50 oC for 3 days.
The solvent was then removed under reduced pressure and the crude product was
triturated with hexanes, filtered, and rinsed with hexanes (4 × 5 mL). The product was
further purified by preparatory HPLC (0-50% EtOAC:hexanes) and isolated as a white
solid (38 mg, 72% yield). 1H NMR (400 MHz, CDCl3) δ 14.83 (s, 1H), 9.14 (s, 1H), 7.98
(dd, J = 8.4, 1.2 Hz, 2H), 7.72 – 7.63 (m, 1H), 7.56 (dd, J = 10.5, 4.8 Hz, 2H), 4.77 (t, J =
1.5 Hz, 2H), 4.04 (s, 3H), 2.85 (s, 2H), 1.35 (s, 6H). LCMS retention time: 3.508 min;
LCMS purity at 215 nm = 96%. HRMS m/z calculated for C19H21N2O4S2 [M++1]:
405.0937, found 405.0942.
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2-(3-benzoylthioureido)-5,5-dimethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylic acid (SID 85747738/ CID 1067700). 2-(3-benzoylthioureido)-5,5-dimethyl5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid was purchased from Chemdiv Inc.
(CAS 314042-01-8) and purified by mass-directed reverse-phase chromatography to
yield a white solid (6 mg). 1H NMR (400 MHz, DMSO) δ 14.84 (s, 1H), 13.39 (s, 1H),
11.81 (s, 1H), 7.98 (dd, J = 1.2, 8.4, 2H), 7.74 – 7.62 (m, 1H), 7.55 (t, J = 7.7, 2H), 4.67
(s, 2H), 2.75 (s, 2H), 1.24 (s, 6H). 13C NMR (101 MHz, DMSO) δ 174.43, 166.86,
165.35, 146.72, 133.08, 132.06, 129.10, 128.75, 128.41, 124.09, 116.50, 70.14, 58.82,
37.27, 26.19. LCMS retention time: 1.871 min; LCMS purity at 214 nm = 92.8%. HRMS
m/z calculated for C18H19N2O4S2 [M++1]: 391.0781, found 391.0777.

2-(3-benzoylthioureido)-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic
acid (SID 9931128/ CID 46916263). To tert-butyl 2-(3-benzoylthioureido)-5-methyl-5,742

dihydro-4H-thieno[2,3-c]pyran-3-carboxylate (0.028 g, 0.065 mmol, 1 eq.) was added a
40% v/v solution of trifluoroacetic acid in dichloromethane (2.5 mL). After stirring the
solution for 4 hours at rt, the solvent was evaporated in vacuo, and the residue purified by
reverse-phase chromatography to yield the product as a white semi-solid (0.011 g, 0.029
mmol, 46% yield). 1H NMR (400 MHz, Acetone) δ 8.07 (d, J = 7.4, 2H), 7.68 (t, J = 7.0,
1H), 7.56 (t, J = 7.5, 2H), 4.76 (q, J = 14.7, 2H), 3.82 – 3.68 (m, 1H), 3.05 (d, 1H), 1.47
(d, J = 6.5, 1H), 1.32 (d, J = 6.1, 3H).
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C NMR (126 MHz, Acetone) δ 175.37, 166.92,

165.37, 161.89, 148.65, 134.12, 133.28, 131.39, 129.62, 129.28, 126.49, 71.61, 65.11,
35.05, 21.82. LCMS retention time: 3.095 min; Purity at 214 nm = 93.3%. HRMS m/z
calculated for C17H17N2O4S2 [M+ + 1] 377.0624, found 377.0622.

tert-butyl 2-amino-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylate. A
mixture of 2-methyldihydro-2H-pyran-4(3H)-one (0.320 g, 2.80 mmol, 1 eq), tert-butyl
cyanoacetate (0.44 mL, 3.08 mmol, 1.1 eq), sulfur (0.099 g, 3.08 mmol, 1.1 eq),
morpholine (0.36 mL, 4.21 mmol, 1.5 eq), and ethanol (7 mL) was heated at 50 °C for 16
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hours. The reaction mixture was then filtered, and the filter cake washed with ethyl
acetate (20 mL). Purification by silica gel chromatography (0-30% EtOAc:Hex ramp
over 20 min) afforded the desired product tert-butyl 2-amino-5-methyl-5,7-dihydro-4Hthieno[2,3-c]pyran-3-carboxylate as a pale yellow solid (0.745 g, 2.77 mmol, 99 % yield).
1

H NMR (400 MHz, CDCl3) δ 5.90 (s, 2H), 4.71 – 4.49 (m, 2H), 3.82 – 3.65 (m, 1H),

2.86 – 2.73 (m, 1H), 2.52 – 2.37 (m, 1H), 1.52 (d, J = 1.4, 9H), 1.31 (dd, J = 2.1, 6.2,
3H).

tert-butyl 2-(3-benzoylthioureido)-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylate. To a solution of tert-butyl 2-amino-5-methyl-5,7-dihydro-4H-thieno[2,3c]pyran-3-carboxylate (0.104 g, 0.386 mmol, 1 eq) in dry ethanol (1 mL)under argon was
added benzoyl isothiocyanate (0.15 mL, 1.08 mmol, 2.8 eq). The mixture was heated at
reflux for 16 hours. The solvent was evaporated in vacuo. Purification by reverse-phase
chromatography (10-100% CH3CN: Water ramp over 20 min) afforded the desired
product tert-butyl 2-(3-benzoylthioureido)-5-methyl-5,7-dihydro-4H-thieno[2,3-c]pyran3-carboxylate as a pale yellow oil (0.057 g, 0.132 mmol, 34 % yield). 1H NMR (400
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MHz, DMSO) δ 14.72 (s, 1H), 11.89 (s, 1H), 8.06 – 7.95 (m, 2H), 7.69 (t, J = 7.4, 1H),
7.57 (t, J = 7.7, 2H), 4.78 (d, J = 14.8, 1H), 4.66 (d, J = 15.0, 1H), 3.80 – 3.63 (m, 1H),
2.93 (d, J = 16.7, 1H), 2.50 – 2.44 (m, 1H), 1.59 (s, 9H), 1.30 (d, J = 6.1, 3H).

tert-butyl 5,5-dimethyl-2-(3-phenylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran3-carboxylate. . To a solution of tert-butyl 2-amino-5,5-dimethyl-5,7-dihydro-4Hthieno[2,3-c]pyran-3-carboxylate (0.100 g, 0.353 mmol, 1 eq) in dry tetrahyrofuran (5
mL) under argon was added phenyl isothiocyanate (0.05 mL, 0.388 mmol, 1.1 eq). The
mixture was heated at reflux for 16 hours. The solvent was evaporated in vacuo.
Purification by reverse-phase chromatography (0-100% CH3CN: Water ramp over 20
min) afforded the desired product tert-butyl 5,5-dimethyl-2-(3-phenylthioureido)-5,7dihydro-4H-thieno[2,3-c]pyran-3-carboxylate as a yellow solid (0.045 g, 0.108 mmol, 30
% yield). 1H NMR (400 MHz, DMSO) δ 11.92 (s, 1H), 11.05 (s, 1H), 7.50 (d, J = 7.6,
2H), 7.42 (t, J = 7.9, 2H), 7.26 (t, J = 7.3, 1H), 4.61 (s, 2H), 2.65 (s, 2H), 1.53 (s, 9H),
1.23 (s, 6H).
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5,5-dimethyl-2-(3-phenylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3carboxylic acid (SID 99381127/ CID 1280844). To 5,5-dimethyl-2-(3phenylthioureido)-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxylic acid (0.037 g, 0.088
mmol, 1 eq.) was added a 40% v/v solution of trifluoroacetic acid in dichloromethane
(2.5 mL). After stirring the solution for 4 hours at rt, the solvent was evaporated in vacuo
and the residue purified by reverse-phase LCMS to yield the product as a white solid
(0.020 g, 0.065 mmol, 63% yield). 1H NMR (400 MHz, Acetone) δ 7.97 (d, J = 7.7, 2H),
7.88 (t, J = 7.7, 2H), 7.73 (t, J = 6.9, 1H), 4.32 (s, 2H), 3.11 (s, 2H), 1.73 (s, 6H). LCMS
retention time: 3.113 min; Purity at 214 nm = 100%. HRMS m/z calculated for
C17H19N2O3S2 [M+ + 1] 363.0832, found 363.0829.
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Results
Identification of CID1067700 as an inhibitor of nucleotide binding by Rab7
CID1067700 was identified as an inhibitor of GTP-binding using a high throughput
screen that was described previously in the context of an allosteric Rho GTPase inhibitor
(135). Briefly, six sets of beads (each with a unique red fluorescence intensity) were
individually coated with six representative GST-tagged Ras-related GTPases (Cdc42 wt,
Rac1wt, Rac1Q61L, Rab2 wt, Rab7wt, and H-Ras wt) (Fig. 6a). The individually
conjugated beads were then assayed in the presence of individual compounds in the
Molecular Libraries Small Molecule Repository using HyperCyt flow cytometry to
identify molecules that altered the binding of fluorescent nucleotide to Ras-family
GTPases (136). CID1067700 (Fig. 6b), was identified as a hit that decreased fluorescent
nucleotide (GTP) binding in the primary screen and was confirmed in secondary,
multiplex dose response assays to have an EC50 of 20-500 nM and at least 40% inhibition
against all tested GTPases (Fig. 6c). CID1067700 was the only compound identified in
the screen to have significant inhibitory activity against the Rab GTPases (Rab2 and
Rab7). Because of its pronounced inhibitory effect (>80%) on Rab7 and the absence of
any known chemical inhibitors for Rab-family GTPases, I further characterized the
mechanism of CID1067700 inhibition using Rab7 as a model protein.
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Figure 6. Identification of CID1067700 as a pan GTPase inhibitor using highthroughput screening on small GTPases. (a) Schematic diagram of the bead based
assay used to measure fluorescent guanosine triphosphate (GTP) binding by flow
cytometry to glutathione-S-transferase (GST)–GTPase chimeras immobilized on GSHbeads. For HTS beads of varying red fluorescence intensities were used as identifiers for
individual protein-conjugated bead sets. (b) Chemical structure of CID1067700 an
inhibitor of nucleotide binding.
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Figure 6. (c) Activity of CID1067700 against multiple GTPases measured as residual
nucleotide binding activity (BODIPY-GTP, 100 nM) in the presence of increasing
concentrations of compound. (d) Nanomolar concentrations of CID1067700 inhibit
Rab7wt protein nucleotide binding; BODIPY-GTP (100 nM, filled squares) and
BODIPY-GDP (40 nM, filled triangles).
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Dose dependent inhibition of Rab7 nucleotide binding by CID1067700
Single-plex dose response measurements were used to determine the effect of
CID1067700 on nucleotide binding by Rab7 small GTPase. To achieve this, the
BODIPY-GDP and BODIPY-GTP concentrations in the assay were fixed to the
previously determined equilibrium dissociation constants (Kd=100 nM BODIPY-GTP;
Kd=40 nM BODIPY-GDP) for the wild-type (wt) Rab7 protein (133). Increasing
CID1067700 concentrations resulted in strong inhibition of both BODIPY-GDP and
BODIPY-GTP binding by Rab7wt with EC50 values of 25 nM for BODIPY-GTP and 40
nM for BODIPY-GDP (Fig. 6d). The deduced efficacy of inhibition was 80% for
BODIPY-GTP and 60% for BODIPY-GDP. These results demonstrate high efficacy and
potency of the CID1067700 molecule with respect to inhibition of Rab7 nucleotide
binding. Maximum inhibition by CID1067700 occurred at 1-10 µM CID1067700
concentration range. Lower inhibitory efficacy against BODIPY-GDP binding may either
represent a preference for one nucleotide conformer over another by Rab7 or the
established higher affinity of Rab7 for GDP than for GTP (133, 137).
Inhibition of Rab7wt nucleotide binding by CID1067700 could be effected through
allosteric or competitive binding. To distinguish between the two scenarios, we tested the
inhibition of Rab7wt by CID1067700 under conditions where CID1067700 concentration
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was held at a fixed concentration (100-200 nM) while increasing the concentration of the
fluorescent nucleotide competitor (Fig. 7a-h). These values were equivalent to
approximately 5 times the observed EC50 for CID1067700 using each of the two
nucleotides. The inhibitory effect of CID1067700 was most pronounced at lower
nucleotide concentrations, resulting in an overall rightward shift of the dose response
curves (Fig. 7b, d). Significantly, both control (DMSO only) and inhibitor (CID1067700
treated) curves had statistically similar Bmax values that correspond to the number of
binding sites on Rab7 (Fig. 7a, c). Thus, at high concentrations, the nucleotide out
competes the CID1067700 compound for the binding pocket, accounting for the Bmax
values that are not statistically different. In contrast, there was ≤3-fold increase in the
observed EC50 for both nucleotides in the presence of CID1067700 indicating
competition of nucleotides by the inhibitor. Calculated inhibitor constants (Ki) for both
nucleotides (Table 1) show a 2-fold increase between inhibition of BODIPY-GTP and
BODIPY-GDP confirming that CID1067700 is better at inhibiting BODIPY-GTP
binding than BODIPY-GDP binding. Analysis of the constitutively active Rab7Q67L and
dominant negative Rab7T22N mutants, that mimic the GTP-bound and GDP-bound
conformers respectively showed that both were similarly inhibited by CID1067700 (Fig.
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7e-h). The composite data suggest that the CID1067700 compound and the nucleotide
most likely compete for the nucleotide binding pocket of Rab7.
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Figure 7. CID1067700 competitively inhibits BODIPY-linked nucleotide binding by
wild type and mutant forms of Rab7. (a-b) CID1067700 (100 nM) does not alter
Rab7wt Bmax for BODIPY-GTP, but does alter apparent EC50 for GTP (filled squares);
observed as a rightward shift of log plot of BODIPY-GTP binding by Rab7wt. (c-d)
CID1067700 (200 nM) does not alter Rab7wt Bmax for BODIPY-GDP; but does alter
apparent EC50 for GDP (filled triangles); observed as rightward shift of log plot of
BODIPY-GDP binding by Rab7wt.
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Figure 7. (e-f). CID1067700 (100 nM) does not alter constitutively active Rab7Q67L
mutant Bmax for BODIPY-GTP, but does alter apparent EC50 for GTP (filled squares);
observed as a rightward shift of log plot of BODIPY-GTP binding by Rab7Q67L. (g-h)
CID1067700 (200 nM) does not alter Rab7T22N Bmax for BODIPY-GDP; but does alter
apparent EC50 for GDP (filled triangles); observed as rightward shift of log plot of
BODIPY-GDP binding by Rab7T22N. In all experiments, equilibrium binding reactions
performed in 1% DMSO served as the controls (open circles).
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Table 1. Equilibrium binding parameters deduced from Figure 7.
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CID1067700 does not affect nucleotide release by Rab7
To further confirm the mode of Rab7 nucleotide inhibition by CID1067700, we
analyzed the fluorescent nucleotide dissociations rates from Rab7 in the presence of
CID1067700. The experiment was carried out by pre-binding BODIPY-GTP or –GDP to
GST-tagged Rab7 protein up to equilibrium nucleotide exchange point and then assaying
for the loss of fluorescence over time occasioned by the release of bound nucleotide (Fig.
8a-d). As a competitor, we used CID1067700 (10 µM) or unlabeled GDP (10 µM).
Dissociation rate constants were calculated from data fit to exponential functions using
Prism software. Koff values of Rab7wt obtained at room temperature were statistically
similar between unlabeled GDP and CID1067700 competitor for both BODIPY-GTP or –
GDP (Table 1). Together the data confirm that the CID1067700 compound has no effect
on the rate of release of bound fluorescent GTP or GDP by Rab7, ruling out allosteric
binding of the CID1067700 inhibitor in preference to competitive binding to the
nucleotide pocket.
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Figure 8: CID1067700 has no effect on the rate of release of bound BODIPY-linked
nucleotide by wild type Rab7 under equilibrium binding conditions. (a) Rab7 was
pre-incubated with BODIPY-GTP (100 nM) for 2 h 15 min at 4°C, conditions that allow
nucleotide binding to equilibrium. Dissociation assays were initiated by dilution +/- the
addition of either CID1067700 (10 µM) or unlabeled GDP (10 µM) and decrease in
fluorescence due to nucleotide dissociation was measured in real time. (b) Two-phase
exponential analysis of a, normalized by subtraction of dilution only values. (c). Rab7
was preincubated with BODIPY-GDP (40 nM) for 2 h 15 min at 4°C as for (a).
Dissociation assays were initiated by dilution +/- CID1067700 (10 µM) or unlabeled
GDP (10 µM) and decrease in fluorescence due to nucleotide dissociation was measured
in real time. (d) Single phase exponential analysis of c, normalized by subtraction of
dilution only values.
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In another approach, in the absence of excess unlabeled GTP, CID1067700 and
BODIPY-nucleotide competitively substitute for each other at the binding site when
direct ligand competition was assayed. BODIPY-GTP or GDP (25-200 nM) was allowed
to bind Rab7wt protein for 100 s in the absence of DMSO or CID1067700. At the
indicated times, either 1% DMSO or 10 µM CID1067700 (final) was added as
fluorescent nucleotide loading was allowed to continue in real time (Arrows, Fig. 9a-b,
9d-e). Relative to DMSO, addition of CID1067700 resulted in an immediate reduction in
further nucleotide binding/loading. Statistical normalization of the fluorescence in the
CID1067700 treated samples, revealed maximal competition between BODIPY-GTP and
CID1067700 when the inhibitor was in 50-fold excess over the nucleotide (200 nm
BODIPY-GTP vs. 10 µM) (Fig. 9c). Thus, binding of CID1067700 behaves as the rate
limiting step in this circumstance. In contrast, BODIPY-GDP outcompetes CID1067700
with nearly complete efficacy (Fig. 9f).
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Figure 9: CID1067700 precludes nucleotide loading through direct displacement of
fluorescent nucleotide. (a-c) Rab7 first incubated with BODIPY-GTP and then 1%
DMSO final added at the point indicated by an arrow or (b) Rab7 first bound with
BODIPY-GTP and then 10 µM of CID1067700 final added at the point indicated by an
arrow and (c). Normalization of (b) reveals competition between BODIPY-GTP and
CID1067700 at 200 nM concentration of the BODIPY-GTP and that binding of
CID1067700 is the rate limiting step. (d-f) Rab7 first bound with BODIPY-GDP and then
1% DMSO final added at the point indicated by an arrow or (e). Rab7 first bound with
BODIPY-GDP and then 10 µM CID1067700 final added at the point indicated by an
arrow and (f). Normalization of (e) reveals that BODIPY-GDP outcompetes CID1067700
better than BODIPY-GTP. Comparison made with (c).
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Nucleotide binding kinetics in the presence of CID1067700 indicates competitive
mechanism
To obtain an alternative confirmation of the mechanism of CID1067700 inhibition and
therefore binding kinetic parameters, real time on rate kinetic measurements were made
using bead-based flow cytometry, as previously described (133). Varying the
concentration of CID1067700 over a 10-fold range revealed that the compound saturates
binding sites on Rab7 at 1 µM concentration (Fig. 10a and Fig. 10d). On-rate kinetic
measurements of BODIPY-GTP and BODIPY-GDP binding in the presence of a fixed
concentration of CID1067700 (1 µM for maximum inhibition) or DMSO control (2 min
pre-incubation) revealed CID1067700 decreased Rab7 BODIPY-nucleotide (GTP and
GDP) binding over a 4-fold nucleotide concentration range (Fig. 10b-c, e-f). Statistically,
there was no effect on the observed association rate constant (kob), a parameter that may
reflect the affinity of nucleotide for Rab7. Kinetic analyses corroborated the equilibrium
binding data and supported a competitive inhibition of Rab7 nucleotide binding by
CID1067700.
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Figure 10: CID1067700 has a fast binding equilibrium and reduces the apparent
number of binding sites for fluorescent nucleotide on wild type Rab7. (a) Rab7wt
was preincubated with either 1% DMSO (blue) or CID1067700 (0.1 or 1µM) for 2 min at
4°C before addition of 100 nM BODIPY-GTP or (b-c) Rab7wt pre-incubated with either
1% DMSO or CID1067700 (1 µM) for 2 min at 4°C before addition of (50-200 nM)
BODIPY-GTP. (d). Rab7wt was preincubated with either 1% DMSO (blue) or
CID1067700 (0.1 or 1µM) for 2 min at 4°C before addition of 40 nM BODIPY-GDP. (ef) Rab7wt pre-incubated with either 1% DMSO or CID1067700 (1 µM) for 2 min at 4°C
before addition of (50-200 nM) BODIPY-GDP. Baseline fluorescence reading shown for
first 50s after which kinetics of BODIPY-nucleotide binding was measured for 200s.
Added nucleotide concentration ranged from 50-200 nM are color coded.
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Molecular docking of CID1067700 on Rab7wt GDP and GTP bound crystal
structures predicts optimal binding to the nucleotide binding pocket of the GTPconformer
The molecular docking of CID1067700 in the nucleotide binding site of Rab7 as
predicted by the experimental data was examined using molecular docking OpenEye Fred
docking software (Fig. 11a-h). Docking of CID1067700 on the GDP- and GTPconformers of Rab7 revealed that the molecule fills the nucleotide binding pocket of both
conformers in a manner that mimics the nucleotides (Fig. 11a-d). However, the
interaction map revealed that the compound had fewer potential interactions with GDPconformer where the binding pocket is more exposed to solvent, which may also explain
why BODIPY-GDP outcompetes CID1067700 better than the BODIPY-GTP (Fig. 11ef). Comparatively, the good alignment between CID1067700 and GNP where 5,7dihydro-4H-thieno[2,3-c]pyran ring system has the same orientation as guanine ring
system may suggest the binding mode of the small molecule in nucleotide binding
pocket. However, a crystal structure determination study involving both CID1067700 and
Rab7 will be required to confirm the most likely binding mode.
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Figure 11: CID1067700 docks optimally in the nucleotide binding pocket of Rab7 in
the GTP-bound conformation. (a-d) CID1067700 docked in the nucleotide binding site
of Rab7 in the (GNP)- bound (PDB 1VG8) and GDP-bound (PDB 1VG9) conformations.
Molecular docking carried out using Fred docking software. Both GTP or GDP and
CID1067700 are shown simultaneously docked in the pocket for purposes of comparing
their orientations in the pocket.

63

Figure 11. (e-h) Interaction maps for Rab7-GNP vs. CID1067700 and Rab7-GDP vs.
CID1067700 illustrate differences in number and sites of interaction.
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Structure activity analyses identify critical determinants for competitive inhibition

To determine structure activity relationships (SAR), eighteen variants of the parent
compound were evaluated. This preliminary SAR set was obtained through synthetic
effort (11 compounds) or commercial acquisition (7 compounds). The parent scaffold,
represented by CID1067700, was modified in any of three major regions to afford the
initial analog collection. The structural alterations focused on esterification of the
carboxylic acid (R1), geminal substitution changes on the fused pyran ring (R2, R3),
mutation of the ring-fused pyran to an N-methylated ring-fused piperidine, or revision of
the N-acyl thiourea linker (L). Only three of the compounds retained activity in a
multiplex GTPase screen with all other derivatives being inactive (Table 2). The parent
and the three active derivatives were assayed in single-plex dose response assays and
EC50 determined against Rab7 (Fig. 12a-e and Table 5). Esterification of the carboxylic
acid moiety resulted in loss of inhibition, a finding that supports the suggested
participation of this group in hydrogen bonding (Fig. 11). Removal of one or both of the
gem-dimethyl groups from the parental thiophenylpyran structure (R2-R3) resulted in a
10- or 20-fold loss in potency, respectively. The effect on potency observed with the
gem dimethyl substitution suggested an advantageous lipophilic ligand-binding site
interaction that is lost upon substituent removal. Alteration of the N-acyl thiourea linker
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further attenuated potency, as demonstrated by the 35-fold loss in potency observed with
N-acyl urea CID46916265, and the complete loss of activity for thiourea CID1280844
and amide CID740871. While further SAR work is required to attribute specific linker
functionality with preferred binding interactions, these preliminary results indicate that
the orientation of tethered groups, and the length and hydrogen-bonding character of the
linker region are critical to maintaining a beneficial activity profile.
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Table 2: Molecular scaffolds responsible for CID1067700 inhibitory activity
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Figure 12: Structure activity relationships identify importance of linker and Rgroups in inhibitory activity of CID1067700. (a). Fig. 1 (d) included for comparison
with derivatives of CID1067700. (b) Nanomolar concentrations of CID46916263
derivative with only single methyl replacement on the pyran group and intact
carbamothioylamino linker inhibit Rab7wt protein nucleotide binding; BODIPY-GTP
(100 nM, filled squares) and BODIPY-GDP (40 nM, filled triangles). (c) Nanomolar
concentrations of CID46916266 derivative with only two methyl replacement on the
pyran group and intact carbamothioylamino linker inhibit Rab7wt protein nucleotide
binding; BODIPY-GTP (100 nM, filled squares) and BODIPY-GDP (40 nM, filled
triangles).
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Figure 12. (d) Nanomolar concentrations of CID46916265 derivative with only
alteration of the thiourea moiety of the carbamothioylamino linker inhibit Rab7wt protein
nucleotide binding; BODIPY-GTP (100 nM, filled squares) and BODIPY-GDP (40 nM,
filled triangles). (e) Nanomolar concentrations of CID1251121 derivative with alteration
of the carboxylic acid group only do not show any activity towards inhibition of
nucleotide binding by Rab7wt protein.
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Discussion and conclusion

In this chapter, a small molecule (CID1067700) identified from high throughput
screening has been shown to inhibit nucleotide binding by Rab7 in the nanomolar range
with EC50 values of 25 nM for BODIPY-GTP and 40 nM for BODIPY-GDP plus
calculated efficacy of nucleotide binding inhibition of 60% for BODIPY-GDP and 80%
for BODIPY-GTP. Kinetic and equilibrium binding studies demonstrate that the
compound acts as a competitive inhibitor and exhibits a good fit to the nucleotide binding
pockets of both the GTP- and GDP-bound conformations of Rab7. By assaying rate
kinetics of Rab7 nucleotide binding in the presence of CID1067700, we noted a decrease
in the number of BODIPY-GTP and BODIPY-GDP binding sites on Rab7 across the
entire nucleotide concentration range considered. Based on equilibrium dissociation
measurements, we also showed that CID1067700 does not affect how fast or slow Rab7
releases bound nucleotide suggesting that CID1067700 inhibits Rab7 nucleotide binding
through a competitive mechanism.

Initial structure activity relationships demonstrate a dependence on the lipophilic
interactions with the substituted ring-fused pyran, the hydrogen bonding capability of the
carboxylic acid, and the integrity of an extended N-acyl thiourea linker to properly extend
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and orient the tethered aryl functionality. Although our assays have focused on
characterizing the small molecule on Rab7, CID1067700 also exhibits inhibitory activity
on other small GTPases (Fig. 6c). To the best of our knowledge CID1067700 is the first
example of a competitive inhibitor for small GTPases. CID1067700 was found to also
inhibit nucleotide binding by both the Rab7Q67L and Rab7T22N mutants that are known
to be constitutively in the GTP and GDP bound states, respectively (30). Although the
Q67L mutation lies in the nucleotide binding pocket of Rab7, the actual location of the
Gln67 residue in the pocket is remote from all predicted contacts with CID1067700.
From analysis of the crystal structure Thr22 residue is involved in forming interactions
with Mg+2 cofactor which is required for GTP/GDP binding, and although CID1067700
small molecule inhibitor has a similar binding mode to nucleotides, molecular docking
studies suggest that magnesium cofactor may not be essential for its binding. Another
important question that the current findings raise is about the conformational state Rab7
may adopt once bound to CID1067700. This question is significance because Rab7
downstream function in cells is entirely dependent on its active (GTP-bound) state. To
address this question, an in vitro effector protein binding assay was carried out and
demonstrated that when Rab7 is bound to CID1067700, Rab7 is not able to bind its Rab
interacting lysosomal protein (RILP) effector (Appendix C). This suggests that when
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CID1067700 binds Rab7 the complex mimics the inactive GDP conformational state.
This finding is in agreement with data that in cells incubated CID106770 epidermal
growth factor receptor downregulation is impaired, consistent with inhibition of Rab7
function (Hong, Basuray, Sklar and Wandinger-Ness, unpublished observation).

Implications and significance of CID1067700 functional inhibition of Rab7

The identification of CID1067700 as a competitive inhibitor of Rab7 nucleotide
binding presents an exciting and novel route to characterize Rab family proteins. Most
small molecules reported to be active against low molecular GTPases are allosteric
inhibitors and have activities that are restricted to the Rho-family GTPases based on their
mechanism of action of blocking GEF interactions with Cdc42, Rac1 and RhoA (138).
Thus, the identification of CID1067700 together with analyses of structure activity
relationships suggest that it may be possible with further development to prepare more
specific analogs with unique advantages when compared to traditional approaches of
studying cell physiology such as conditional knock out or RNA interference as a means
to perturb Rab GTPase functionality. Small molecules also can be applied to cells to
rapidly and often reversibly inhibit targets. This is exemplified by Brefeldin A, an
allosteric inhibitor of Arf GTPases (13) and inhibitors of phosphoinositide 3-kinases that
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have been shown to inhibit specific kinase isoforms (139, 140). Moreover, Rab7 function
depends on numerous protein-protein interaction partners including hVps39 (141),
TBC1D15 (109, 142), RILP (36, 129, 143), ORPIL (65, 78), Rabring7 (83, 84) and the
alpha proteasome subunit XAPC7 (71, 82) whose interaction with Rab7 may be potential
candidates for small molecule modulation. A small molecule might also be useful for
dissecting the order of protein binding to a multimeric complex and/or the importance of
nucleotide for stability of the protein complex involving Rab7. Taken together, our
findings present CID1067700 as a novel competitive inhibitor of small GTPase
nucleotide binding that has potential for dissecting protein function in vitro. It may serve
as a springboard for further development of families of compounds selective for
individual GTPases like members of the Rho family of GTPases.
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CHAPTER THREE
FUNCTIONAL CHARACTERIZATION OF RAC1 USING
R-NAPROXEN ISOFORM
Abstract
Abnormal function of Rho family GTPases has been associated with human tumors of
the colon, breast, lung, head and neck. Because of their roles in cell adhesion and
migration, Rho family GTPases have been suggested as potential therapeutic targets in
human cancers. In collaborative studies, Rac1 is identified as over expressed in human
ovarian cancer and thus a novel target. Inhibition of Rac1 GTPase function by the RNaproxen isoform is demonstrated, and shown to be distinct from the commercially
marketed S-Naproxen. R-Naproxen was initially identified by flow cytometry based high
throughput screening of the Prestwick compound library as a select non-steroidal antiinflammatory drug (NSAID) that targets Rac1. R-Naproxen inhibits EGF-stimulated
Rac1 activation as well as altering sub-cellular localization of Rac1 and its guanine
nucleotide exchange factor (GEF), Tiam1 at physiologically relevant doses. In vitro
assays show that R-Naproxen does not inhibit Rac1 interaction with its Tiam1 guanine
exchange factor (GEF). Molecular docking predicts that R-Naproxen can favorably bind
the nucleotide pocket of the GDP-bound Rac1, but not the GTP-bound Rac1, suggesting
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potential inhibition through stabilization of the inactive protein. Taken together, the
findings present R-Naproxen as a potential therapeutic molecule for further consideration
in metastatic ovarian cancer research.

Introduction

Like the Rab family, Rho GTPases play important and diverse roles that ensure normal
cellular physiology. Ten diﬀerent mammalian Rho GTPases, some with multiple
isoforms; Rho (A, B, C isoforms), Rac (1, 2, 3 isoforms), Cdc42 (Cdc42Hs, G25K
isoforms), Rnd1\Rho6, Rnd2\Rho7, Rnd3\ RhoE, RhoD, RhoG, TC10 and TTF have
been identified to date (144). Rho, Rac and Cdc42 GTPases are the most characterized
members though more research continues to accumulate in this area. Currently, about 22
genes encoding different members of the Rho family have been identified in the human
genome (145).

Functional role of Rac1

The primary role of Rho GTPases is centered on the assembly and organization of the
actin cytoskeleton. In response to extracellular cues, activation of Rho, Rac, or Cdc42
small GTPase leads to the assembly of contractile actin:myosin filaments, protrusive
actin-rich lamellipodia, and protrusive actin-rich filopodia, respectively (146-150). The
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effects on the actin cytoskeleton suggest well coordinated signal transduction pathways
controlled by each GTPase leading to both the formation (actin polymerization) and the
organization (filament bundling) of actin filaments. The integrity of the cytoskeletal
network influences processes such as cytokinesis(151-153), phagocytosis (154, 155),
pinocytosis (148), cell migration (156, 157), morphogenesis (158) and axon guidance
(159). These processes are highly impacted in various disease conditions like cancer. A
member of the Rho family of GTPases particularly associated with coordination of cell
proliferation, adhesion, and migration/invasion is Rac1. Among the Rac isoforms, Rac1
is ubiquitously expressed, Rac2 is a hematopoietic lineage-specific GTPase regulating
superoxide generation via the NADPH oxidase in phagocytes, and Rac3 is expressed
primarily in the brain (160-163).

The role of Rac1 in cell proliferation has been demonstrated through several findings.
In cholangiocarcinomas cells, it was shown that blocking Rac1 using siRNA significantly
suppressed cell proliferation and induced apoptosis (164). In another study, knock down
of Rac1 using siRNA was found to impair proliferation of bovine aortic endothelial cells
(165). In MDA-MB-231 cells, blocking of Rac1 using NSC23766, a small molecule
which inhibits Rac1 interaction with its Tiam1 GEF, was reported to induce G1 cell cycle
arrest and prevent cell proliferation (138). Rac1 activation is also associated with
76

cadherin-mediated cell-cell adhesion (166). This was demonstrated in normal human
keratinocytes where expression of dominant negative N17Rac1 was found to inhibit ECadherin mediated cell-cell adhesion (167).

Cell migration plays a central role in processes such as embryonic development,
wound repair, inflammatory response and tumor metastasis. The migrating cell requires
actin-dependent protrusions at the front and contractile actin:myosin filaments at the rear
besides stabilization of microtubules originating from the centrosome in the direction of
migration (168-170). These actin based structures are to enhance targeted vesicle
trafficking from the Golgi apparatus to the leading edge. Rac1 functioning in concert with
WAVE and Arp2/3 promotes cell migration at the leading edge where it induces the
formation of actin-rich lamellipodia protrusions, serving as the major driving force of cell
motility (156, 171-174). In chemotaxing neutrophils, accumulation of Rac1 at the leading
edge is aided by PI(3)-kinase and its product, phosphatidylinositol 3-phosphate (PI3P)
(175). In neutrophil models, it has been shown that the polarized accumulation of PIP3 is
aided by localization of the lipid phosphatase PTEN to the sides and rear of the migrating
cell (176, 177). In addition to WAVE and Arp2/3 proteins in cell migration, the
functional role of Rac1 in cell migration is also dependent on other interacting effector
proteins. For example; DOCK180 which despite lacking requisite DbI homology77

pleckstrin homology (DH-PH) tandem domain, regulates GDP-GTP exchange of Rac and
facilitates its cell migration role (178, 179).

In disease conditions such as cancer, processes of cell proliferation, adhesion, and
migration are key determinants of disease severity. More often the lethality of cancer is
heavily influenced by how far the tumor cell has spread from the point of origin. This
situation thus makes therapeutic targeting of Rac1 as well as Rac1 driven migratory
processes a tractable strategy. As alluded to above, whether under physiologically normal
conditions or in disease states, all Rac1 associated functions do not occur in isolation but
rather depend on their interaction with regulatory effector molecules.

Regulation of Rac1

Like the Rabs, Rho GTPases also undergo prenylation prior to membrane recruitment
(146). They equally cycle between an active GTP-bound state and an inactive GDPbound state (Fig. 1). This transition is similarly controlled by (a) Rho guanine nucleotide
exchange factors (GEFs) (180); (b) Rho GTPase- activating proteins (GAPs) (181); and
(c) Rho guanine nucleotide dissociation inhibitors (GDIs), that block spontaneous
activation (182). Many Rho GEFs were originally identified as oncogenes after
transfection of immortalized fibroblast cell lines with cDNA expression libraries (183).
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Characteristically, nearly all Rho GEFs share DH (Dbl homology) domain adjacent to a
PH (pleckstrin homology) domain features. Notable among the Rho GEFs is the T-cell
invasion and metastasis 1 (Tiam1) protein. Tiam1 was originally identified in a retroviral
insertional mutagenesis screen of murine T-lymphoma cells (184). Tiam1 possesses the
characteristic Dbl homology (DH)–pleckstrin homology (PH) domain combination and is
widely expressed (185). The Tiam1 protein consists of two N-terminal PEST domains, an
N-terminal PH domain (PHn), a coiled-coil region with adjacent sequence (named CCex) (186, 187), a Ras-binding domain (RBD) (188), a PSD-95/DlgA/ZO-1 domain and
the characteristic catalytic DH–PH (named PHc) combination.

In the cell, Tiam1 is primarily localized on the membranes, an environment found to
be crucial to its induction of Rac-mediated membrane ruffles and activation of c-Jun Nterminal kinase (187). While the presence of a lipid domain is key to Tiam1 GEF
activity, phosphorylation is another event that may directly trigger its membrane
translocation and/or GEF activity. Tiam1 is reported to be phosphorylated on threonine
residues by Ca2+/calmodulin kinase II (CaMK-II) and protein kinase C (PKC) in vitro and
upon treatment of Swiss 3T3 fibroblasts with lysophosphatidic acid (LPA) and PDGF in
vivo (189-191). Thanks to virtual screening and rationale design, the small molecule
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NSC23766 was identified and confirmed as an inhibitor of Rac1 interaction with Tiam1
(138).

Like the GEFs, a large number of Rho GTPase family GAPs have been identified to
date (181). For the case of Rac1, β2-chimaerin, ArhGAP1, and YopE have been
identified to possess GAP activity (192-194). As opposed to YopE, which possesses GAP
activity towards Rac1, Rho and Cdc42 (193), β2-chimaerin GAP activity was shown to
be phospholipid dependent and more specific towards Rac1 than Rho and Cdc42 (194).
In both Rab7 and Rac1 GTPases, the regulatory process involving GEFs, GAPs and
effector molecules is conceptually analogous to an electronic circuit system in which
GEFs act as electronic signal amplifiers, while GAPs that inactivate the GTPase present
as signal attenuators. Effector molecules that couple GTP bound (active) GTPase proteins
with downstream signaling events are analogous to electronic signal integrators. Granted
the dependence of Rab or Rho GTPase function on partner molecules, careful elucidation
of both regulatory factors and effectors is crucial for effective implementation of
therapeutic strategies taking into consideration the need to avoid pathways with
functional redundancies.
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Association of Rac1 GTPase with human disease: Rac1 and cancer

Mounting evidence has linked Rho GTPases with cancer development (Appendix D)
(195-198). Abnormal function of Rho GTPases has been associated with human tumors
of the colon, breast, lung, head and neck, and ovary (199-203). A member of the Rho
GTPases widely expressed in several human cancers is Rac GTPase (204-206). Its role in
cell migration is a key determinant of tumor cell metastasis (Fig. 13).
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Figure 13: Rho family of GTPases in tumor metastasis. Rac1 is involved in processes
leading to loss of cell polarity, loss of cell-cell junctions and cell motility. Rho like Rac1,
regulates processes that coordinate loss of cell polarity and multilayering, loss of cell-cell
junctions and cell motility. These are characterized by formation of stress fibers and focal
adhesion that in turn ensure both amoeboid and mesenchymal migration. Cdc42 is
associated with processes that establish normal cell polarity as well as migratory polarity
with the latter marked by protrusive actin-rich filopodia at the leading edge of the cell.
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The role played by Rac1 GTPase in cancer pathogenesis has been well documented. In
proliferating epithelial breast cells and breast cancer, Rac1 protein was found to be highly
expressed and to be linked to metastasis of these cells (207). In the same vein, in a breast
cancer cell line, inhibition of Rac1 using Rac inhibitor EHT1864 down-regulated ERα
expression and breast cancer cell proliferation (208). ERα plays a critical role in the
pathogenesis of the breast cancer disease (209-211). Another group showed that Rac1 is
critically involved in non-small cell lung adenocarcinoma (NSCLA) cell migration,
invasion and lung metastasis of SP cells (212) which echoed previous research linking
tumorigenesis in LSL-K-rasG12D mouse model of lung adenocarcinoma with the
expression levels of Rac1 (213).

In many colorectal cancers, Rac1 or the Rac1 specific GEF (Tiam1) is over expressed
(214-216). Tiam1 in colorectal cancers is a transcriptional regulator of the canonical Wnt
signalling pathway (215, 217). The synergy of Rac1 and Tiam1 expression levels in
colorectal cancers correlate with the findings that showed that an interplay of Rac1 and
Tiam1 modulates Wnt target gene transcription by associating with the β-catenin/TCF
transcription factor complex at Wnt-responsive promoters (218). Dysregulation in Wnt
signaling is associated with the development of many cancers including colorectal cancer
(219). The role of Rac1in some cancers sometimes may depend on a more complicated
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pathway. For example, in SKOV3 ovarian cancer cell line, the Rac1 role in cancer
development was found to be dependent on the Crk/Dock180/Rac1 pathway (220) and
important in ovarian cancer cell proliferation, motility and invasion (220).

Ovarian cancer occurs with high prevalence, killing about 20,000 women annually
(221, 222). Most cases of ovarian cancer are diagnosed when the cancer has already
spread, leading to 5-year survival rate of less than 40 % (222). The main reasons behind
this poor prognosis are: (i) lack of understanding of the molecular underpinnings of the
disease and (ii) predominant localization of ovarian cancer cells within the peritoneal
region which complicates early diagnosis (222). At the molecular level, one strategy for
addressing the ovarian cancer problem is through targeting a protein that is directly
associated with cancer cell metastasis such as Rac1 GTPase. This strategy is not only
vital in the context of having a grasp of the ovarian cancer disease etiology but also may
present Rac1 as a potential therapeutic target in ovarian cancer disease.

For many years, dominant negative mutants of Rac have been the preferred choice in
studying Rac function in cells. However, given the difficulty of introducing high
concentrations of the Rac mutants into primary cells coupled with non-specific effects of
the mutants on effector molecules such as Rho guanine nucleotide exchange factor (GEF)
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activities, it has become desirable to explore the use of small molecules to target Rac
activities. Different strategies have been applied for this purpose. In one approach small
molecules to modulate Rac1 nucleotide binding and therefore interfere with downstream
events linked to Rac1 activation have been developed. One such inhibitor is EHT1864
(223). Functionally, EHT1864 inhibits Rac family GTPases by placing Rac1 in an inert
and inactive state (guanine nucleotide displacement mechanism) and thus impairing
Rac1-mediated functions in vivo (223). The second approach involves small molecule
interference of Rac1 protein-protein interactions with the best characterized one being
NSC23766 specific inhibition of Rac1-Tiam1 interaction (14, 14, 138, 224-226).

A strategy for targeting Rac1 protein function through non-steroidal anti-inflammatory
drugs (NSAIDs) has established by the Wandinger-Ness lab in collaboration with
Hudson, Sklar and colleagues. NSAIDs are commonly used for pain management and
best known for their inhibitory activity on cyclooxygenase enzymes. Preliminary data
accumulated from high throughput screening (HTS) performed by the UNM Center for
Molecular Discovery suggested that Rac1 may be functionally regulated by NSAIDs
(unpublished). The limited, documented studies on the use of NSAIDs to manage human
cancer have tended to be mainly epidemiological with little thrust on the molecular basis
of the disease (227-229), which may provide beneficial effects in terms of cancer stage
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and age of onset. It was therefore the aim of the dissertation work to elucidate how the
NSAID drug, Naproxen, may regulate Rac1 protein function in an ovarian cancer cell
line.
Naproxen comes in two isomeric forms, R-isomer and S-isomer (Fig. 14). Both have
the same chemical formula but different conformations in space at the chiral center (230).
The two different conformations can induce different chemical behaviors between the
two isomeric forms that will be shown in the results section. This is in line with the
increasing experimental evidence showing that chiral NSAIDs inhibit both COX-2 and
COX-1 isoenzymes with comparable stereoselectivity (231, 232). For instance, in an in
vitro system of guinea pig whole blood, lipopolysaccharide (LPS)-stimulated human
monocytes, and purified preparations of COX-2 from sheep placenta, S-enantiomers of
ketoprofen, flurbiprofen, and ketorolac were found to display exclusive inhibitory effect
on COX-2 enzyme as opposed to COX-1 (232). In cancer studies as well, R-etodolac was
shown to be better at inducing apoptosis of prostate cancer cells than the S-etodolac
(233). In this study, we provide evidence that the R-enantiomer of Naproxen as opposed
to the S-enantiomer functionally inhibited Rac1 and its associated downstream cellular
processes in ovarian cancer cell lines. A related NSAID, 6-methoxy-2-napthalene acetic
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acid (6-MNA) compound (Fig. 14) which is structurally very similar to Naproxen but
lacks chiral center was used as a negative control.

Figure 14: Molecular structures of the NSAID compounds used in the study
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Materials and Methods

Reagents

Reagents used in this part of the study were obtained from different sources as
indicated. G-LISATM Rac Activation Assay kit (Cytoskeleton, Denver, CO, USA),
RhoGEF exchange assay kit (Cytoskeleton, Denver, CO, USA), DMEM and MEM media
(Invitrogen, Carlsbad, CA, USA) and c-Myc Tag IP/Co-IP Kit (Thermo Fisher
Scientific, Rockford, IL, USA). R-Naproxen, S-Naproxen and 6-methoxy-2-napthalene
acetic acid (6-MNA) were obtained from the chemical library of off patent drugs
(Prestwick, Washington DC, USA), Sigma-Aldrich (St. Louis, MO, USA) and Cayman
Chemical (Ann Arbor, MI, USA), respectively.

Rac1 activation assay in the presence of Naproxen

The Rac1 activation assay was carried out using G-LISATM Rac Activation Assay kit
procedures (Cytoskeleton, Denver, CO, USA). The principle of the assay is based on the
interaction of active Rac (Rac-GTP) with its p21-kinase (PAK1) effector. The bound
active Rac is detected with a Rac specific antibody. The extent of Rac activation is based
on the absorbance readings (read at 490 nm) between the activated cell lysates versus
non-activated cell lysates. The assay was carried out in Swiss 3T3 fibroblast and
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OVCA433 cell lines. Swiss 3T3 cells are known to a show robust Rac1 activation upon
EGF stimulation and were therefore used for baseline kinetic measurements. The Swiss
3T3 cells were cultured in DMEM media (DMEM, L-glutamine, Penicillin/Streptomycin
antibiotic and fetal calf serum) and then subjected to a two-step starvation by sequentially
scaling down the concentration of fetal calf serum (FCS). The OVCA433 cells were first
cultured in MEM media (MEM, L-glutamine, Penicillin/Streptomycin

antibiotic and 10% fetal calf serum) for 24 h and then starved for 24 h in the culture
media containing 0.1 % bovine serum albumin (BSA). A time course of EGF-dependent
Rac1 activation was first carried out in both cell lines without any small molecule. This
established 2 min of EGF stimulation for maximal Rac1 activation.

In the presence of small molecule, the starved OVCA433 cells were appropriately
treated for 1 hour with R-Naproxen (300 µM final), S-Naproxen (300 µM final), and 6MNA (300 µM final) dissolved in aqueous buffer system. To enhance the dissolution of
R-Naproxen and 6-MNA in aqueous buffers, the pH of the solution had to be adjusted to
at least 8.0 using 40 mM Tris-Base while S-Naproxen was dissolved in double distilled
water. One set of treated cells was then stimulated with EGF (10 ng/ml final) for 2
minutes before harvesting and storing the cell lysate as per prescriptions of the G-LISATM
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Rac Activation Assay kit. The starved Swiss 3T3 cells were subjected to a time
dependent treatment with R-Naproxen and 6-MNA before stimulation with EGF (10
ng/ml) for 2 minutes. Harvesting and storage followed the same procedure as for the
OVCA433 cells.

Rac1 guanine exchange factor (GEF) assay in the presence of Naproxen

The Rac1 GEF assay was carried out according to the protocol outlined in the RhoGEF
exchange assay kit, BK100 (Cytoskeleton, Denver, CO, USA). Immunoprecipitated myctagged Tiam1 was used in the assay for GEF activity. HeLa cells were cultured for
transfection using standard cell culture procedures. At 80% confluency, the cells were
transfected with myc-Tiam1 plasmid using LipofectamineTM 2000. The cell lysate was
harvested according to procedures stipulated in the c-myc tag IP/co-IP kit (Thermo
Scientific, Pierce Biotechnology, Rockford USA) and then stored at -80oC. To carry out
the Rac1 GEF assay in the presence of small molecule, the following procedure was
adopted. Phosphatidylinositol 4,5-bisphosphate (PIP2) lipid in CHCl3: MeOH:H2O
mixture was dried under vacuum and then redispersed in immunoprecipitation elution
buffer (50 µl) using intermittent bath sonication and vortexing. The equivalent of 10 µM
of PIP2 lipid (final) was incubated with 1 µM Myc-Tiam1 (full length) solution for 5
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minutes at room temperature as reported earlier (234) and then put on ice. His-Rac1 (45
µM final) constituted in sterile water was mixed with nucleotide exchange buffer (20 mM
Tris-HCl pH = 7.5, 50 mM NaCl, 10 mM MgCl2, 5 % BSA and 0.75 µM Mant-GTP) in a
100 µl volume (final) in a light sensitive 96 well plate. 1 % DMSO (final), 100 µM RNaproxen in 1 % DMSO (final) and 100 µM 6-MNA in 1 % DMSO (final) were then
added accordingly. The mixture was briefly shaken on a bench top shaker for 30 sec
before further incubation for 5 minutes at room temperature. Initial fluorescence
measurements were obtained for 5 minutes on the fluorimeter plate reader (1420
Multichannel counter, PerkinElmer) by exciting mant-GTP at 360 nm and recording
emitted fluorescence at 440 nm. PIP2 lipid bound Myc-Tiam1 (10 µM final) was then
added to appropriate wells and fluorescence changes monitored. Control wells in the
assay consisted of Rac1 treated with H2O only and 1% DMSO. PIP2 served as a Tiam1
GEF activator in the assay by binding lipid homology domains of Tiam1 (234).

Molecular docking of R-Naproxen on Rac1
Docking calculations were performed using OpenEye Fred (Fred, version 2.2.5,
OpenEye Scientific Software, Inc., Santa Fe, NM, USA, www.eyesopen.com, 2010)
docking software. Rac1 crystal structure (PDB code: 1I4D) was used to dock RNaproxen on Rac1 wild type crystal structure. Chemgauss3 scoring function was used to
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evaluate ligand binding potential. Docking simulations provide only a qualitative
assessment of binding probability of R-Naproxen ligand to Rac1 and should be examined
with care.

R-Naproxen inhibition of COX enzymes relative to S-Naproxen
The R-Naproxen inhibitory effect on COX enzymes relative to S-Naproxen was
assayed by a contracted commercial company (CEREP, Seattle, USA). The following
procedures obtained from CEREP were used. For COX-1, the test compound, reference
compound or water (control) were first pre-incubated for 20 min at 22°C with the enzyme
(≈ 5 µg) in a buffer containing 90 mM Tris-HCl (pH 8.0), 2 mM phenol and 1 µM
hematine. Thereafter, the reaction was initiated by adding 4 µM arachidonic acid and the
mixture incubated for 5 min at 22°C. Following incubation, the reaction was stopped by
the addition of 1 M HCl then 1 M Tris/HCl (pH 8.0) followed by cooling to 4°C. For
basal control measurements, arachidonic acid was omitted from the reaction mixture.
The fluorescence acceptor (D2-labeled PGE2) and the fluorescence donor (anti-PGE2
antibody labeled with europium cryptate) were then added. After 120 min, the
fluorescence transfer was measured at λex=337 nm, λem=620 and λem=665 nm using a
microplate reader (EnVision, Perkin Elmer). The enzyme activity was determined by
dividing the signal measured at 665 nm by that measured at 620 nm (ratio). The results
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were finally expressed as a percent inhibition of the control enzyme activity. The
standard inhibitory reference compound was diclofenac, which was tested in each
experiment at several concentrations to obtain an inhibition curve from which its IC50
value was calculated.

On the other hand, the approach followed to assay inhibition of COX-2 enzyme was
slightly different from that used for COX-1. The test compound, reference compound or
water (control) were pre-incubated for 20 min at 22°C with the enzyme (≈ 0.2 µg) in a
buffer containing 90 mM Tris-HCl (pH 8.0), 2 mM phenol and 1 µM hematine.
Thereafter, the reaction was initiated by addition of 2 µM arachidonic acid and the
mixture was incubated for 5 min at 22°C. For basal control measurements, arachidonic
acid was also omitted from the medium. Following incubation, the reaction was similarly
stopped by the addition of 1 M HCl then 1 M Tris/HCl (pH 8.0) followed by cooling to
4°C. Fluorescence acquisition and calculation of percent inhibition were then carried out
in the same way as in the COX-1 assay. Unlike in the case of COX-1, they used NS398
as the standard inhibitory reference compound.
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Results

R-Naproxen inhibits Rac1 GTPase in ovarian (OVCA433) and Swiss 3T3 cell lines

As discussed previously, Rac1 plays a critical role in several aspects of tumorigenesis,
cancer progression, invasion, and metastasis. Rac proteins are overactive or overexpressed but not mutated in most invasive human cancers. In this study, isomeric RNaproxen was used to characterize Rac1 function in ovarian cancer (OVCA433) and
Swiss 3T3 fibroblast cell lines with and without EGF stimulation. This quantitative assay
takes advantage of the interaction between activated Rac1 (Rac1-GTP) and GST tagged
p21-activated kinase (PAK1) effector mobilized on a well. PAK1 is one of the six
members of the family of serine/threonine protein kinases functioning as an effector of
Rho GTPases (235). PAK1 controls the dynamics of cell motility by linking a variety of
extracellular signals to changes in actin cytoskeleton organization, cell shape, and
adhesion dynamics besides modulating cell division, apoptosis, and gene transcription
processes (236). PAK1 pull down depends on Rac1 being in the GTP-bound state.

To obtain the optimum time point where maximum Rac1 activation occurs, the two
cell lines used in the study were first subjected to time dependent EGF stimulation. The
premise is that prior to EGF stimulation, serum starvation of the cells keeps Rac1 GTPase
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predominantly in the GDP state (in the cytosol) such that EGF stimulation triggers a
cascade of events that activate Rac1 and convert it to the GTP-bound state. As shown in
Fig. 15a-b, both OVCA433 and Swiss 3T3 fibroblast cell lines showed maximum EGF
dependent Rac stimulation after 2 min of treatment. Swiss 3T3 cells were included in the
study not only to elucidate R-Naproxen effect on Rac1 in a non-cancerous cell line but
also due to its robust response to EGF stimulation. Pretreatment of Swiss 3T3 cells with
R-Naproxen yielded a time dependent inhibition of EGF-dependent Rac1 activation, with
maximal inhibition after 1 h of drug pretreatment (Fig. 15c). While the 1 hr R-Naproxen
treatment of Swiss 3T3 cells reduced EGF stimulated Rac1 activation to a level
comparable to the serum starved basal level of Rac-GTP, treatment with 6-MNA
followed by EGF stimulation showed modest and statistically insignificant inhibition of
Rac1 activation. Time dependent inhibition of Rac1 by R-Naproxen suggests that Rac1
may be a direct target of R-Naproxen in Swiss 3T3 cells. OVCA433 cells were treated
with a fixed therapeutically relevant concentration of R-Naproxen, S-Naproxen and 6MNA (300 µM) for 1 hour before stimulating cells with EGF for 2 min. R-Naproxen
blocked EGF-mediated activation of Rac1 relative to S-Naproxen and 6-MNA treated
sets (Fig. 15d). Given that the assay measures levels of Rac1-GTP, the results obtained
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show that R-Naproxen, but less so S-Naproxen, acts as an inhibitor of Rac1 activation in
cell based assays.
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Figure 15: R-Naproxen blocks epidermal growth factor mediated Rac1 activation in
OVCA433 and Swiss 3T3 cells. (a) Time course of epidermal growth factor mediated
Rac1 activation in Swiss 3T3 cells. (b). Time course of epidermal growth factor mediated
Rac1 activation in OVCA433 cells. (c). 300 µM R-Naproxen pretreatment blocks
epidermal growth factor mediated Rac1 activation in Swiss 3T3 cells in a time dependent
way. (d). 300 µM R-Naproxen blocks epidermal growth factor mediated Rac1 activation
in OVCA433 cells after 1 h treatment. Both OVCA433 and Swiss 3T3 cells stimulated
with EGF for 2 min during drug treatment.
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As an independent measure of Rac1 activation status in the presence of R-Naproxen
treatment, the active Rac1 membrane bound pool and the overall protein levels of Rac1
were measured by a combination of immunofluorescence and Western blot analyses.
Findings are shown in Fig. 16a-c. R-Naproxen reduced the membrane bound pools of
Rac1 (Fig. 16a) and its Tiam1 GEF (Fig. 16b) without affecting overall protein levels of
Rac1 (Fig. 16c), in agreement with the Rac1 GLISA data. Compared to R-Naproxen,
treatment of OVCA433 cells with the NSAIDs of Aspirin, Ibuprofen, Fenoprofen and
Ketoprofen did not cause appreciable/significant redistribution of Rac1 from the plasma
membrane to the cytosol (Appendix E). In a wider context, inhibition of Rac1 is
predicted to impair actin based processes of cell proliferation, adhesion and migration.
Dr. Laurie Hudson (collaborator in the project) and colleagues measured the effects of RNaproxen on ovarian cancer cell proliferation, adhesion and migration and determined
that, R-Naproxen inhibited all the three actin based processes, a finding which correlated
with inhibition of Rac1 GTPase activation. Studies conducted on OVCA429 cells by an
undergraduate student in the laboratory, Anna Vestling, also showed that R-Naproxen but
not 6-MNA, inhibited formation of protrusive actin-rich lamellipodia, and protrusive
actin-rich filopodia (unpublished), which correlated with inhibition of Rac1 and Cdc42
GTPases respectively.
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Figure 16: R-Naproxen blocks membrane localization of Rac1 and Tiam1 in
OVCA433 cells. (a) Rac1 redistributes from the plasma membrane in the presence of 300
µM of R-Naproxen. (b). Quantification of fluorescence intensity from immunostaining of
Rac1 in OVCA433 cells. (c). R-Naproxen does not affect overall protein levels of Rac1
in OVCA433 cells. The cells were treated for 1 hr with R-Naproxen or indicated NSAID.
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Based on these results, first, we hypothesized that R-Naproxen could be interfering
with interaction of Rac1 with its regulatory proteins such as GEFs and if that held, it
would qualify R-Naproxen as an allosteric inhibitor in a cellular context (138, 237-239).
Second, we hypothesized that R-Naproxen might be stabilizing Rac1 in a GDP-bound
(inactive) state in a non-competitive fashion. Both cases can technically lead to less
Rac1-GTP and interfere with downstream effector activation and actin remodeling
required for proliferation, migration and invasion. To address these hypotheses, an in
vitro qualitative assay was established to directly test the effect of R-Naproxen on Rac1
interaction with Tiam1 GEF.

R-Naproxen small molecule does not interfere with Tiam1 GEF activity on Rac1
under in vitro conditions.

A Tiam1 GEF-Rac activation assay is described in the methods section. Myc-Tiam1
protein was purified by immunoprecipiation for use in the assay. Tiam1 was first shown
to be active as a Rac1 GEF in the presence of the phosphatidylinositol 4,5-bisphosphate
lipid activator +/- 1% DMSO (Fig. 17a). DMSO did not interfere with Tiam1 driven GEF
response (Fig. 17a). His-Rac1 was treated with 100 µM of R-Naproxen or 6-MNA and
assayed for mant-GTP binding in the presence of Tiam1 GEF. Contrary to the first
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hypothesis, no inhibition of Tiam1 mediated guanine nucleotide exchange by Rac1 was
observed in the presence of either R-Naproxen or 6-MNA (Fig. 17b-c) suggesting that RNaproxen may not be binding the switch regions of Rac1. R-Naproxen could be
inhibiting Rac1 in the cell lines assayed via a different mechanism yet to be elucidated.
This then prompted us to assess if molecular docking prediction could yield a clue on the
most probable binding site of R-Naproxen on Rac1 and if so, that may be used as a guide
for designing future alternative experimental approaches to assay the mechanism of RNaproxen inhibition of Rac1 function.

101

Figure 17: R-Naproxen does not block Rac1 interaction with Tiam1 GEF. (a)
Controls showing Tiam1 GEF activity effect on Rac1 treated with water and 1 % DMSO.
(b). Rac1 undergoes normal Tiam1 mediated transition to GDP bound state when treated
with 100 µM R-Naproxen, 1 µM Tiam1 and 10 µM of phosphatidylinositol 4,5bisphosphate lipid. (c) Rac1 undergoes normal Tiam1 mediated transition to GDP bound
state when treated with 100 µM µM 6-MNA, 1 µM Tiam1 and 10 µM of
phosphatidylinositol 4,5-bisphosphate lipid. Phosphatidylinositol 4,5-bisphosphate binds
and activates the lipid homology domain of Tiam1.
102

Molecular docking of R-Naproxen on GDP bound Rac1 predicts possible binding of
R-Naproxen to the nucleotide binding pocket
Molecular docking of R-Naproxen in the nucleotide binding pocket of GDP bound
Rac1 was prompted by experimental data obtained from cell based assays as well as the
in vitro Tiam1 GEF assay. The docking was performed using molecular docking
OpenEye Fred docking software. The docking results (Fig. 18) predict that GDP bound
Rac1 state relative to the GTP bound Rac1 is the most favorable orientation which may
allow R-Naproxen to form H-bonds with Thr17 and Asp57 residues in the nucleotide
binding pocket. Further examination showed that R-Naproxen may also form hydrogen
bonds with Mg+2 cofactor in the nucleotide pocket via Naproxen carboxylic group. The
GTP bound state of Rac1 is missing the nucleotide binding pocket orientation present in
the GDP bound state which can accommodate R-Naproxen molecule. This suggests that
R-Naproxen may prefer the GDP bound Rac1 and thus may explain results obtained in
OVCA433 and Swiss 3T3 cells.

Compared to R-Naproxen, the docking of S-Naproxen yielded an unfavorable
orientation of carboxyl oxygen with respect to favorable interaction with Mg2+ and
formation of H-bonds with Thr17 and Asp57 amino acid residues. Thr17 residue is
required for Rac1 activation (240). Taken together, both in vitro and cell based
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experimental results present R-Naproxen as a small molecule that can functionally inhibit
Rac1 in ovarian cancer cell lines. Future studies will test the mechanism of action
predicted by Cheminformatic analysis (Fig. 18).
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R-‐NAPROXEN	
  
GDP	
  

Figure 18: R-Naproxen docks optimally in the nucleotide binding pocket of GDP
bound Rac1 (a-b) R-Naproxen docked in the nucleotide binding site of Rac1 in the
(GDP)- bound (PDB code: 1I4D) conformation. Molecular docking carried out using
Fred docking software. Both GDP and R-Naproxen are shown simultaneously docked in
the pocket. (c) Interaction map for Rac1-GDP and R-Naproxen showing potential
hydrogen bonding involving R-Naproxen.

105

Discussion and conclusion

Use of cyclooxygenase (Cox) inhibitors to modulate cancer is a field gaining currency.
Rho GTPases are increasingly being targeted in cancer research due to overwhelming
evidence suggesting either overexpression or deregulation of some Rho GTPases
downstream signaling components in a number of human cancers (241, 242). While
many studies have delineated the downstream effectors of RhoA, Rac1 and Cdc42 as
responsible for tumor growth and metastasis, direct targeting of these small GTPases with
small molecules is an area which has not received significant attention. In this study, data
is presented on the functional characterization of Rac1 using off patent molecules of
Naproxen and 6-MNA non-steroidal anti-inflammatory drugs (NSAIDs). Rac1 is shown
to be functionally inhibited by the R-Naproxen isoform in ovarian cancer (OVCA433)
cells and Swiss 3T3 fibroblast cells at physiologically tolerable concentrations. This is
characterized by lower levels of activated Rac1 (GTP bound) and redistribution of Rac1
from the plasma membrane in the presence of R-Naproxen. Functional inhibition of Rac1
by R-Naproxen is correlated with inhibition of cell-cell adhesion and cell migration in
ovarian cancer cell lines (Hudson unpublished observations). The functional role of Rac1
in ovarian cancer cells is similar to reported role of Rac1 in NSCLA SP cells where Rac1
was found to regulate cell migration, invasion and lung metastasis (212).
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Earlier studies have reported that Rho GTPases are involved in the alteration of cell–
cell adhesion status of tumor cells (243). Rho GTPases alter adhesion by coordinating the
disassembly as well as destabilization of E-cadherin based adhesions (244, 244). Rac1 in
particular has been shown to promote disassembly of cadherin-dependent adhesion via its
interaction with PAK1 effector (245). Together, these studies reinforce our findings that
the inhibition of cell-cell adhesion by R-Naproxen correlates with functional inhibition of
Rac1. R-Naproxen was shown to alter Tiam1 distribution in the plasma membrane in
OVCA433 cells even though it did not prevent in vitro Rac1-Tiam1 interaction. The
observed Tiam1 membrane re-distribution is consistent with loss of OVCA433 cell-cell
junction and migratory ability. Previous in vitro studies have revealed that Tiam1mediated Rac activation is required for proper cell junction formation (246). This is
further backed by a study which showed that loss of Tiam1 promotes EMT in vitro and
the progression of mouse skin tumours in vivo (247, 247). There is also evidence
suggesting that Tiam1 promotes apical-basal cell polarization in epithelial cells as well as
promoting directional migration in freely migrating epithelial cells (246, 248, 248). Thus
R-Naproxen dependent loss of Tiam1 from the membrane of OVCA433 cells may
contribute to the inhibition of migration and invasion. Like other small GTPases,
interaction between Rac1 and its regulatory proteins such as Tiam1 occurs via the switch
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1 and switch 2 regions.

In the present study, a possible explanation for the inability of R-Naproxen to inhibit
Rac1-Tiam1 interaction is that the mode of interaction involving Rac1 and R-Naproxen
may not involve the Rac1 switch regions. One possible R-Naproxen binding site may be
the Rac1 nucleotide binding pocket. As a prelude to address the most likely mode of
action of R-Naproxen, we have employed a cheminformatics approach to show that RNaproxen can be docked on the nucleotide binding pocket of GDP bound Rac1 relative to
that of the GTP bound Rac1. This molecular docking prediction is based on the
hypothesis that R-Naproxen by binding the nucleotide binding site of Rac1, may stabilize
Rac1 in the GDP state.

R-Naproxen like other NSAIDs is a cyclooxygenase (COX) enzyme inhibitor.
NSAIDs are known to inhibit the activity of both COX-1 and COX-2, a characteristic that
accounts for their shared therapeutic and side effects (249). Their ability to inhibit both
enzymes has to a large extent been attributed to physico–chemical parameter of
lipophilicity (250). While the inhibition of COX-2 accounts for their common use as antiflammatory drugs, inhibition of COX-1 may explain their often unwanted side effects
such as gastric damage (249, 251). Different processes ranging from inflammation to
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diseases such as cancer have been linked to COX-2 upregulation (252, 253). In terms of
drug response, different NSAIDs including R-Naproxen manifest different inhibitory
potency levels against COX-1 and COX-2 isoenzymes (Appendix F; Glaser et al. Eur J
Pharmacol, 1995, 281, 107-11; Dannhardt and Kiefer, 2001, Eur J Med Chem, 36, 10926). In the data obtained by contracted commercial entity (CEREP, Seattle, USA), RNaproxen relative to S-Naproxen, shows lower potency against both COX-1 and COX-2
enzymes (Appendix F). This further emphasizes the impact of stereoselectivity between
the two isoforms of Naproxen. In addition to their known function as COX inhibitors,
NSAIDs have been shown to have off target effects that may contribute to their in vivo
effect. Examples include modulation of γ-secretase enzyme, inhibition of the Rho small
GTPase and its associated kinase Rock, inhibition of translocation of the transcription
factor NF-κB which activates many genes that promote inflammation, induction of mda7/IL-24 expression and inhibition of vascular endothelial growth factor production among
others (254, 255). All these off target effects are contextually relevant in different disease
states.

In this study, R-Naproxen is shown to be a novel inhibitor of Rac1 activity in
OVCA333 and Swiss 3T3 cells via COX enzyme independent pathway. This is premised
on the fact that structurally similar 6-MNA which like Naproxen is a classical COX
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inhibitor, did not yield statistically significant inhibitory effect on Rac1 activation and
associated cellular processes in the cell lines considered. More so, there are documented
studies in different cancer cell lines showing that COX-2 activation occurs downstream
of Rac1 activation (256, 257). The data shown hear together with other data that are part
of a comprehensive collaborative study show that R-Naproxen inhibits Rac1 driven
processes of ovarian cancer cell migration, invasion and proliferation. These are key
processes that define tumor cell metastasis and therefore the study presents Rac1 as a
novel therapeutic target in ovarian cancer.

Implications and significance of R-Naproxen functional inhibition of Rac1

There are significant and potential spinoffs of the current study. More importantly, it
has presented a relatively easy route for Rho GTPase targeting in cancer using small
molecule. Naproxen is an off patent and cost effective molecule which has survived all
the rigors of drug development and therefore can be safely used in patients. Secondly,
since the role of Rac1 in actin remodeling is coordinatively linked to other molecules,
questions can be posed as to how R-Naproxen (by inhibiting Rac1 activation) may affect
associated partners such as assembly of the downstream Arp2/3 complex (258, 259),
nucleating promoting factors (260, 261) and insulin receptor tyrosine kinase substrate p53
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(IRSp53) (262). These proteins are intimately associated with Rac1 function in actin
remodeling and associated processes of migration and invasion. Functional inhibition of
Rac1 also presents an opportunity to target other members of Rho GTPases that together
with Rac1 define cancer metastasis. There is a need to assess how R-Naproxen isoform
may functionally modulate Rho (A, B or C) and Cdc42 GTPases in the context of ovarian
cancer.

There is already published evidence on the inhibition of RhoA GTPase associated
signaling pathway by NSAID, Ibuprofen. The latter was shown to surmount axon growth
restrictions from myelin and proteoglycans by potently inhibiting downstream pathway
linked to RhoA (263). The same study also reported that, like Rho and Rock inhibitors,
Ibuprofen stimulated significant neurite growth in cultured dorsal root ganglion neurons.
This was confirmed by an independent group which also showed that Ibuprofen reduces
ligand-induced Rho signaling and myelin-induced inhibition of neurite outgrowth in vitro
(264). There are also suggestions that ibuprofen and its derivatives may prevent
Alzheimer's disease by modulating astrocyte reactivity through Rho-GTPase/PAK/ERKdependent signaling (265). All these precedents affirm the need to investigate how RNaproxen may modulate Rho small GTPase function in cancer models. Preliminary
findings by Elsa Romero in the Wandinger-Ness laboratory suggest that R-Naproxen also
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inhibits Cdc42 activation in Swiss 3T3 cells (unpublished) that correlates with disruption
of Cdc42 membrane localization in OVCA429 cells (Vestling, unpublished). Both
findings suggest that Rho GTPase may also be a potential R-Naproxen target since Rac1,
Cdc42 and Rho GTPases are functionally interdependent.
It is important to point out that RhoA and Rac1 are involved in the control of the
levels of matrix metallopro-teinases (MMPs) that degrade the extracellular matrix (ECM)
in addition to influencing the remodeling of the ECM by regulating tissue inhibitors of
metalloproteinases (TIMPs) (245). Degradation of the ECM is a key ingredient in cancer
cell migration which therefore makes RhoA targeting by R-Naproxen plausible approach.
It has also been reported that Tiam1 functionally upregulates the transcription of TIMP-1
and posttranslational levels of TIMP-2 in renal-cell carcinomas (266). This also presents
an option to investigate if R-Naproxen by causing Tiam1 redistribution from the plasma
membrane, also affects the levels of TIMP-1 and TIMP-2.

Another point for potential extrapolation of the study is in ovarian cancer animal
models. Establishing Rac1 functional inhibition by R-Naproxen in animal models will not
only strengthen the current in vitro findings but may also act as a platform for
translational clinical research applying Naproxen molecule in a cancer context. Taken
together, this study has shown that Rac1 GTPase and associated cellular processes can be
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potential targets in ovarian cancer. It has also established that a commonly used NSAID
Naproxen can be used to target molecular pathways in cancer, a finding which may offer
potential therapeutic opportunities. In a wider context, this study joins the rank of other
investigations centered on understanding molecular processes dictating ovarian cancer
metastasis and how small molecules can be used to modulate them.
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CHAPTER FOUR

FUTURE PERSPECTIVES

Abstract

Different strategies can be employed to characterize a small GTPase protein using a
small molecule. In this dissertation, it has been shown that CID1067700 small molecule
competitively inhibits nucleotide binding by Rab7 while R-Naproxen allosterically
inhibits Rac1 function. Both small molecules can potentially be optimized as probes for
selective targeting of small GTPases. These findings present an important route as far as
understanding how these important proteins are regulated in diverse cellular processes.
To date, only few cases about use of small molecules to selectively target small GTPase
proteins exist much as they dictate the progress of a number of diseases. The best
examples include small molecule specific inhibition of Golgi trafficking by the fungal
metabolite brefeldin A and prenylation inhibitors. The latter are however complicated by
lack specificity since the approach may target a plethora of GTPases. The situation thus
necessitates the need to explore other small molecules whether allosteric or competitive
modulators that may be adapted for selective small GTPase targeting. The entire small
GTPase activation cycle presents diverse points for potential small molecule intervention
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that may ultimately provide new ideas on mechanism of action. From prenylation
inhibitors to protein-protein interactions modulators, research on small molecules
targeting small GTPases may open a new window of opportunity with respect to
identifying new therapeutic targets in disease states as well as enabling an easier way of
characterizing protein function.

Characterized molecular targets and precedents emerging from the current study

There have been some limited attempts to find small molecule modulators of small
GTPase proteins of Rab and Rho sub-families. The small molecules that have been
characterized to date have centered on modulation of membrane association, nucleotide
binding or exchange, and inhibition of protein-protein interactions (Fig. 19). The strategy
of blocking membrane recruitment through inhibition of protein prenylation (267), has
proven to be effective even though it is limited due to the broad cellular importance of
lipid modifications for the proper functioning of many GTPase families among other
proteins. Currently, prenylation inhibitors are primarily geared towards targeting Ras
GTPases. A major disadvantage of such compounds, however, is the lack of
specificity/selectivity required for many applications due to overlapping inhibitor activity
against farnesyl transferases and geranylgeranyl transferases. That notwithstanding, the
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quest for more specific prenylation inhibitors against the GTPases is aggressively being
pursued (10, 11, 268, 269, 269, 270). Even if not specific, the prenylation inhibitor results
suggest that the strategy of delocalizing GTPases from membranes can be effective in
some cases.
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Figure 19. Regulation of small GTPases and potential small molecule modulation
sites. Newly synthesized small GTPases are modified on C-terminal cysteine residues by
lipid moieties (prenyl or farnesyl chains) to ensure membrane recruitment via REP. GEFs
and GAPs analogously act as small GTPase signal activators and attenuators,
respectively. GDI serves to regulate membrane-cytosol cycling. Potential points for
targeted intervention through small molecules are denoted by brackets.
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Another approach for modulating small GTPase function by small molecule is through
the inhibition of regulatory protein interactions (Fig. 19). Some of the characterized
examples include the fungal metabolite brefeldin A which has been successfully studied
as an inhibitor of ADP-ribosylation factor 1 (Arf1) GTPase (271, 272). Brefeldin A
functions by targeting specific guanine nucleotide exchange factors (GEFs), including
Golgi complex-specific Brefeldin A resistance factor 1 (GBF1). A stable complex of
Brefeldin A-GDP-Arf1-GEF on membranes prevents GDP/GTP exchange of Arf1 on
membrane surfaces and disrupts Golgi morphology (273). Among the Rho-family of
GTPases, GEF inhibitors such as NSC23766 and its analogs have been identified and
characterized as allosteric regulators of protein-protein interactions that block Rac1
interaction with its GEF protein partners (14, 274). In our context, R-Naproxen may also
modulate Rac1 function in cells via an allosteric mechanism by binding a site distinct
from the nucleotide binding site. This may be marked by a direct or indirect inhibition of
Rac1 interaction with its regulatory proteins. Inhibition of Rac1 in this way can be
significant in situations such as cancer metastasis where blocking of Rac1 dependent cell
migration is important. While some GEF small molecule inhibitors for the Rho family of
GTPases have been characterized, none have yet been translated to clinical trials possibly
due to the immense cost of preclinical studies and drug development of new chemical
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entities. Hence the application of an FDA approved molecule could have significant
advantages.

The therapeutic success and selectivity of competitive adenine nucleotide binding
inhibitors for targeting tyrosine kinases provided the impetus for screens to identify
guanine nucleotide binding small molecule inhibitors of GTPases (Fig. 19) (135).
Inhibitors may come in different types. They can either be competitive or noncompetitive inhibitors or just activators of nucleotide binding by the GTPase. As
discussed above, there are currently few compounds that have been characterized with
activity against GTPases. EHT1864 is one further example of a small molecule, which is
demonstrated to inhibit Rac family GTPases albeit in a non-allosteric fashion by placing
Rac1 in an inert and inactive state (guanine nucleotide displacement mechanism) and in
the process interfering with Rac1-mediated functions in vivo (223). The screen performed
as a collaboration between the Wandinger-Ness lab and the UNM Center for Molecular
Discovery was the first to comprehensively identify both inhibitors and activators for Rho
and Rab GTPase family members (135). Based on molecular docking prediction, one of
our running hypotheses in this study is that R-Naproxen may modulate Rac1 function in
cells in similar way as EHT1864 does by stabilizing Rac1 in the GDP bound state. If this
holds, it suggests a non-competitive mechanism of inhibition of Rac1 function by R119

Naproxen and significantly, will lead to inhibition of Rac1 associated downstream
signaling events that can also be useful against cancer. The caveat will be if the
specificity of R-Naproxen is sufficient to avoid affecting other GTPases.

Prior to the present study, there were no known competitive inhibitors of nucleotide
binding by small GTPases let alone by the Rab family. Thus, identifying CID1067700 as
a competitive inhibitor of Rab7 nucleotide binding, not only presents a good platform for
characterizing GTPase enzymology, but also opens new possibilities for probe
development that can be extended to other GTPases. One caveat in the use of
CID1067700 for cell based studies may be its potential to act as a pan inhibitor against
other GTPases. However, given the SAR data presented in this study and multiplex
assays performed by Center for Molecular Discovery, chemical modifications show
promise of selectivity for Rab7 as compared to Rho family GTPases. This is consistent
with previous studies from the Wandinger-Ness laboratory that Rab7 showed exquisite
selectivity by binding BODIPY FL GTP analogues labeled on the 2’ or 3’ oxygen of the
ribose ring, but not BODIPY FL GTP-γ-NH labeled on the γ-phosphate (133). RhoA on
the other hand bound both analogues equally well, indicating nucleotide binding pocket
differences that affect small molecule binding.
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In a physiologic context, small molecule activators or inhibitors of small GTPase are
expected to be useful in therapeutic applications for various disease states. For instance,
activators may be useful for diseases where wild-type GTPase expression is reduced or
there is altered activity. Typical examples include, Niemann-Pick type C disease,
Huntington’s disease, Charcot-Marie-Tooth disease, and some cancers and ciliopathies.
On the other hand, inhibitors of guanine nucleotide binding like CID1067700 or allosteric
inhibitors such as R-Naproxen can be useful for blocking activation in cells, and with
refinement of specificity may offer great opportunities for modulating individual
pathways in diseases where overexpression and hyperactivation of GTPases are a
problem, e.g. cancers, neurodegenerative and infectious diseases. Through the
mechanistic assessment of small molecules such as CID1067700 and R-Naproxen, both
an enhanced understanding of the Rab and Rho GTPases with respect to their
coordination with regulatory proteins, downstream effector proteins and their potential
for targeted therapies may be gained.
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APPENDICES
Appendix A. Rab GTPase functions, networks and disease associations. Rab
GTPases are clustered according to their functions in: 1) Endocytosis and recycling; 2)
Degradation, autophagy, phagocytosis and pinocytosis

Rab

GTPase
partners

Localization

Rab Function

Pathological
condition

Reference

Rab4a

Rab5a,
Rab11, Rab14

Early endosomes
and recycling
endosomes

Regulates sorting
and endocytic
recycling to the
plasma
membrane;
trafficking of
human Pglycoprotein
responsible for
multidrug
resistance of
tumors; functions
with Rab14
through shared
effector
RUFY1/Rabip4

Upregulated in
rodent model of
diabetic
cardiomyopathy,
human systemic
lupus
erythematosus,
Alzheimer's
disease and
Down's
syndrome;
inhibited in
Niemann-Pick
disease;
downregulated in
tumor cells

(275-282)

Rab5a

Rab4a,
Rab11,
Rab15, Rab21

Plasma membrane,
clatherin coated
vesicles and early
endosomes

Regulates
endocytosis,
early endosome
fusion, nuclear
signaling through
APPL

Hyperactivated in
lung
adenocarcinoma
due to
upregulated Rin
GEF; upregulated
in Alzheimer's
Disease

(276, 277,
283-287)

Rab9a

Rab7a

Late endosomes

Implicated in
transport from
Endosome to
trans-Golgi
network; lipid
transport;
lysosome and
Lysosome related
organelle

Inhibited in
Niemann-Pick C
disease;
increased
function
beneficial in lipid
clearance in
Niemann-Pick
disease and
Cystic fibrosis;

(288-305)

Endocytosis
and recycling

122

biogenesis

antagonized by
pathogens
Upregulated in
Barrett's
epithelia;
neurodegeneratio
n in Huntington's
disease due to
inactivation;
Schwann cell
demyelination in
Charcot-MarieTooth type 4C
disease caused by
disruption of
SH3TC2-Rab11
intreaction;
Batten disease
disrupts Hook
mediated
interaction of
CLN3 and Rab11

(306-319)

Rab11a, Rab11b
(neuron specific)

Arf4, Rab8a,
Rab10, Cdc42

Golgi and recycling
endosomes, early
endosomes,
phagosomes

Regulates
trafficking from
the trans-Golgi
network to apical
recycling
endosomes and
plasma
membrane;
dopamine
transporter and
beta2-adrenergic
receptor
trafficking;
polarized
trafficking in
epithelia;
phagocytosis in
macrophages

Rab14

Rab4, Rab39

Early endosome,
Golgi

Endocytic
recycling of
transferrin; MHC
class I crosspresentation in
dendritic cells;
TGN to apical
trafficking in
epithelia;
surfactant
secretion in
alveolar cells;
insulin-dependent
GLUT4
translocation;
functions
cooperatively
with Rab4
through shared
effector
RUFY1/Rabip4;
regulation of
embryonic
development
through
interaction with
Kif16B and
transport of FGF

(281, 282,
320-327)

Rab15

Rab5a

Early/sorting
endosome, recycling
endosome

Trafficking
through
sorting/recycling
endosomes to the
plasma membrae;
attenuates Rab5
function

(328, 329)
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Rab17

Recycling
endosome

Epithelial
transcytosis;
polarized
trafficking in
kidney

(330-332)

Rab20

Phagosomes,
mitochondria,
endosomes

Vacuolar ATPase
trafficking in
kidney; target of
HIF in hypoxia
induced
apoptosis;
phagosome
acidification and
maturation; Gap
junction
biogenesis

Modulated by
pathogens;
overexpressed in
pancreatic and
breast cancers

(48, 333-338)

Rab21

Rab5a

Early endosomes;
macropinosomes

Endocytosis of
integrins, cellextracellular
matrix adhesion
and motility;
cytokinesis;
macropinocytosis
shares effectors
and GEFs with
Rab 5 (APPL,
Rabex-5 VARP)

Involved in
cancer cell
motility

(339-348)

Rab22a

Rab5a, Rab7a

Early endosome,
plasma membrane

Transport of
transferrin from
sorting
endosomes to
recycling
endosomes;
pathogen
phagocytosis;
enriched in glia;
shares effectors
and GEFs with
Rab5 (Rabex-5,
EEA1)

Upregulated in
hepatocellular
carcinoma;
mycobacterium
tuberculosis
inhibits
phagosome
maturation by
blocking Rab22a
to Rab7 transition
required for late
endosome fusion
and
phagolysosome
formation

(340, 349356)

Rab25

Rab11a

Recycling
endosome

Apical recycling
in epithelia,
microtubule
dependent
transformation

Tumor
progression and
cancer
invasiveness
(down regulated
in breast and
intestinal cancers;
upregulated in
ovarian cancer
and
hepatocellular
carcinoma)

(306, 347,
351, 357-370)

Trans Golgi
network (TGN) and

Mannose 6phosphate
transport from

Rab31/ Rab22b
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(371)

endosomes

TGN to
endosomes;
enriched in glia;
transport of
proteins involved
in myelination
from TGN to
plasma
membrane via
endosomes

Rab34

Rab7a, Rab36

Golgi and
endosomes

Endosomes,
macropinosome
formation,
phagosome
maturation,
lysosome
morphogenesis,
functions with
Rab36 and Rab7
through shared
effector (RILP)

Diabetic
nephropathy

(48, 372-379)

Rab35

Cdc42

Endosomes and
plasma membrane

Fast endocytic
recycling; MHC
class I and II
endocytosis and
recycling; Tcell
recpetor
recycling;
phosphoinositide
regulation;
neurite outgrowth
through interfaces
with Cdc42; actin
remodeling
through fascin
effector leading
to filopodia
formation

Pathogen
phagocytosis and
trafficking

(380-388)

Rab36

Rab7a, Rab34

Golgi

Late endosome
and lysosome
clustering;
functions with
Rab7 and Rab34
through shared
effector RILP

Potential function
as tumor
suppressor

(372, 389,
390)

Rab39

Rab14

Golgi and early
endosomes, AP1
membrane domains

Caspasedependent-IL1beta secretion;
homology to
Rab14;
phagosomal
acidification

Autophagy,
Phagocytosis
and Degradation
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(48, 325, 391,
392)

Rab7a

Rab5a,
Rab9a,
Rab34, Arf6,
Rac1

Late endosomes and
lysosomes; stage I
and II
melanosomes;
surfactant
endocytosis and
signaling

Transport from
early to late
endosomes and
late endosome to
lysosome fusion;
bidirectional
transport of
signaling
endosomes,
autophagosomes,
multivesicular
bodies, and
melanosomes on
microtubules in
association with
dynein and
kinesin motor
proteins; axon
viability;
phosphoinositide
homeostasis; lipid
transport;
activation of
mTOR signaling;
lung innate and
adaptive
immunity based
on upregulation
in alveolar
macrophages by
surfactant SP-A

Mutant in
Charcot-MarieTooth Disease
Type 2B
(CMT2B);
modified to
promote
intracellular
pathogen
survival;
increased
function
beneficial in lipid
clearance in
Niemann Pick
disease;
upregulated in
Alzheimer's
Disease, thyroid
cancer, diffuse
peritoneal
malignant
mesothelioma,
adult-onset
obesity; mutation
of downstream
effector Vps33b
causal in
arthrogryposisrenal-cholestasis

(21, 27, 30,
32-34, 37, 38,
49, 51, 61, 63,
69, 71, 117,
122, 125, 287,
365, 393-398)

Rab24

Autophagosomes,
nuclear inclusions

Myelination;
autophagosome
formation

Activated in cell
culture models of
neuronal and
cardiomyocyte
injury leading to
the increased
autophagy;
upregulated in
hepatocellular
carcinoma

(351, 355,
399-403)

Rab32

Perinuclear vesicles,
mitochondria,
autophagic vesicles

Post-Golgi
trafficking of
melanogenic
enzymes; ER
stress mediated
apoptosis;
mitochondrial
dynamics

Rab32 gene
methylated in
inflammatory
bowel disease at
transition to
invasive growth

(346, 404408)

Rab33

Golgi,
autophagosomes

Autophagosome
formation;
interacts with
Atg16L

(409, 410)

Rab43

Phagosome

Cathepsin D
transport to
phagosomes

(48)
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APPENDIX B. Rab GTPase effector regulators and associated cellular functions

Rab

Rab Effector

Effector function

References

Rab4a-GTP

Rabaptin-4

Assists in the docking of transport
vesicles en route from early
endosomes to recycling
endosomes

(411)

Rabaptin-5

Activates Rab5 through complex
with Rabex-5 and links Rab5 with
Rab4

(412, 413)

Rabip4

Regulates transport through early
endosomes

(414)

EEA1

Coordinates tethering and fusion

(415-417)

p110beta/p85 PI
3-kinase

Ensures coupling of the lipid
kinase product to its downstream
target, protein kinase B.

(418)

Phosphoinositide
3-kinase
(hVps34/hVps15)

Regulates SNARE complex
formation or disassembly

(419)

Rabaptin-5

Activates Rab5 through a
complex with Rabex-5, Links
Rab5 with Rab4, and facilitates
membrane docking and fusion.

(412, 420, 421)

Rabaptin-5beta

Stabilizes Rabex-5 recruitment
and facilitates membrane fusion
in concert with Rabaptin-5

(421, 422)

Rabenosyn-5

Required for CCV-EE and EE-EE
fusion, regulates the functional
link between Rab5 and Rab4
domains

(423, 424)

Rabip4

Regulates transport through early
endosomes

(414)

Rabex-5

GEF for Rab5

(421, 425, 426)

RIN1

GEF for Rab5 and activated by
growth factor signaling

(427)

RIN2

May function as upstream
activator and downstream effector

(428)

Rab5a-GTP

Rab5a-GDP
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Rab7a-GTP

ANKFY1

Possible role in vesicular
trafficking. Novel interactor of
Rab7. Specific role yet to be
established

(125, 429)

Armus/Rac1

Regulates cytoskeleton
organization, ruffled border
formation in osteoclasts,
inactivates Rab7 and regulates Ecadherin degradation.

(21, 303)

ATP6V0A1

Component of vacuolar ATPase
that regulates organelle
acidification required for protein
sorting, receptor mediated
endocytosis, zymogen activation
and synaptic vesicle proton
gradient. Novel interactor of
Rab7. Specific role yet to be
established

(125, 430)

FYCO1 (FYVE
and coiled-coil
domain
containing 1)

Implicated in microtubule plus
end transport of autophagosomes
presumably through interaction
with kinesin.

(41)

GNB2L1

Role in intracellular signaling and
activation of protein kinase C and
possible interaction with Rab7 via
WD40 domain. Novel interactor
of Rab7. Specific role yet to be
established

(125)

HOPS complex
(Vps11,-16,-18,33,-39 and-41)

Involved in endo-lysosomal
transport. Vps39 binds Mon1Ccz1 complex that serves as a
Rab7 GEF in yeast.

(115, 431, 432)

hVps39

In yeast, cooperates with Mon1Ccz1 complex to promote Rab7
nucleotide exchange.

(141, 431)

IMMT (Mitofilin)

Maintains mitochondrial
morphology and suggested role in
protein import. Novel interactor
of Rab7. Specific role yet to be
established.

(125)

KIF3A (kinesin +
adapter?)

Associates with late endosomes
along with dynein, Rab7 and
dynactin. Possible mediator of
Rab7 regulated anterograde
transport.

(70)

Mon1a-Mon1b

Mammalian homologs of C.
elegans SAND1. Mon1a-Mon1b
causes Rab5 GEF displacement
and Mon1b interacts with the
HOPS complex. HPS1

(116, 433-435)
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ORP1L

Required for activation of dynein/
dynactin motor, regulates late
endosome/lysosome
morphogenesis and transport.

(78)

Phosphoinositide
3-kinase
(hVps34/hVps15)

Regulates activity of Vps34 and
generates PI3P to control
endosomal trafficking and
signaling.

(18)

Plekhm1
[pleckstrin
homology
domain
containing,
family M (with
RUN domain)
member]

Regulates vesicular transport in
osteoclasts.

(304)

Prohibitin

Negative regulator of cell
proliferation and a possible tumor
suppressor. Novel interactor of
Rab7, specific role yet to be
established.

(125)

Rabring7

Rab7 interacting RING finger
protein, functions as E3 ligase
that ubiquitinates itself and
controls EGFR degradation.

(85)

Retromer (Vps26,
Vps29, Vps35)

Regulates retrograde transport
from late endosome to trans-Golgi
network (TGN) through direct
interaction with Vps26.

(436)

RILP (Rab7
interacting
lysosomal
protein)

Involved in late
endosomal/lysosomal maturation.
Recruits dynein-dynactin motor
protein complex.

(69)

Rubicon

Regulates endosome maturation
through differential interaction
with UVRAG and Rab7.

(437)

Spg21

Involved in vesicular transport.
Novel interactor of Rab7. Specific
role yet to be established.

(125, 438)

Stomatin like 2
(STOML2)

Negatively modulates
mitochondrial sodium calcium
exchange. Novel interactor of
Rab7. Specific role yet to be
established.

(125)

TrkA

Interacts with Rab7 and regulates
endocytic trafficking and
signaling as well as influencing
neurite outgrowth.

(33, 439)
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UVRAG/Beclin1

UVRAG/C-Vps complex
regulates Rab7 activity during
autophagic and endocytic
maturation.

(38)

VapB

Involved in vesicular trafficking
and novel interactor of Rab7.
Specific role yet to be established.

(125)

Vps13c

Vacuolar protein sorting and
novel interactor of Rab7. Specific
role yet to be established.

(125)

Ccz1

Recruited to endosomes by
Mon1a/Mon1b and acts as Rab7
GEF in yeast. Possible human
homolog C7orf28B also some
similarity to HPS4 involved in
biogenesis of lysosome related
organelles.

(116, 433-435)

TBC1D5

Negatively regulates retromer
recruitment and causes Rab7 to
dissociate from membrane.

(110)

TBC1D15

Functions as Rab7 GAP. Reduces
its interaction with RILP,
fragments lysosomes and confers
resistance to growth factor
withdrawal induced cell death.

(109, 142)

XAPC7/PSMA7
alpha proteasome
subunit

Negative regulator of late
endocytic transport.
Overexpression inhibits EGFR
degradation.

(71)

Rab7b

SP-A (Surfactant
Protein A)

Transiently enhances the
expression of Rab7 and Rab7b
and makes them functionally
active to increase the
endolysosomal trafficking in
alveolar macrophages.

(398)

Rab8a-GTP

Cpn 0585

Facilitates Rab8 recruitment to
Cpn inclusion membrane

(440)

FIP-2

May be implicated in
morphogenesis

(441)

TRIP8b

Regulates secretory pathway

(442)

MAP4K2
(Rab8IP)

Rab-regulated protein
phosphorylation, secretion
pathway

(286, 443)

Ahi

Ciliogenesis

(444)

Rab7a-GTP,
GDP
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BBSome

Ciliogenesis; cilial transport

(445)

Cenexin3 (OFD2
splice variant)

Binds microtubules and basal
bodies, ciliary biogenesis

(446)

Ellipsa (via
Rabaptin5)

Intraflagellar transport

(447)

FIP-2

Recruitment of Huntingtin to
Rab8-positive vesicular
structures; Polarization

(441)

GDI-2

GDI

(448)

GLUT4

Glucose transport

(449)

JRAB/MICALL2

Adherens junction and tight
junction assembly

(450)

MICAL-L1

EHD1-Rab8a interaction,
membrane tuble localization

(451)

MSS4

Weak GEF or chaparone

(452, 453)

Myosin Vb

Motor - Insulin-induced GLUT4
translocation

(321)

Noc2

Effector

(454)

OCRL1

Phosphatase

(455, 456)

Optineurin/FIP2

Post-Golgi trafficking/exocytosis

(457)

Otoferlin

Trans-Golgi trafficking

(458)

Rabaptin-5

Molecular bridge for intraflagella
transport

(447)

RIM2

Scaffold

(454)

Sro7(Sec4pYeast
homologue)

Potential SNARE regulation

(459)

XM_037557

GAP

(446)

Rabin8

GEF

(460)

Rabin3(rat)

GEF

(460)

Rab8b

TRIP8b

Secretory pathway regulation

(442)

Rab9a-GTP

P40

Mediates late-endosome-to-TGN
vesicular transport

(461)

TIP47

Facilitates MPRs transport

(291)

GCC185

Involved in MPRs recycling

(462)

INPP5B

Could be facilitating secretory

(463)

Rab8a-GDP
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pathway
Rab10

Rab11a-GTP

Cpn 0585

Facilitates Rab10 recruitment to
Cpn inclusion membrane

(440)

EVI5

Potential GAP

(456, 464)

Exocyst

Cilial trafficking

(465)

GDI-1

GDI

(466)

MSS4

Chaparone

(452)

Myosin
Va,Vb,Vc

Motor

(467)

Rim1

Scaffold

(454)

TBC1D4

GAP

(22)

RIP11

Regulates multiple distinct
membrane trafficking events

(468)

RCP

Regulates protein sorting in
tubular endosomes

(469)

FIP5/RIP11

Endocytic recycling; exocytosis

(470)

Evi5

GAP

(471)

FIP3/Arfophilin/
Eferin

Mediate transport to the
endosomal-recycling
compartment, endocytic
regulation, abscission

(472)

Rab11BP/Rabphil
in 11

Vesicle recycling

(286, 473)

Sec15

Exocyst component, endocytic
recycling

(474)

FIP1

Recycling

(475)

FIP4

Recycling, Regulation of retinal
development, abscission

(476)

FIP2

Recycling

(477)

Presenilin 1

Trafficking chaparone

(478)

Presenilin 2

Trafficking chaparone

(478)

PI4-kinase β

Localization of rab11 to the Golgi
complex, post-Golgi trafficking

(479)

Myosin Va

Motor

(476, 480)

Myosin Vb,

Motor

(481)
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D-AKAP2

Endosome morphology and
protein accumulation

(482)

D. melanogaster
nuclear fallout
(Nuf)

Recycling endosomes, Cleavage
furrow membrane integrity, actin
remodeling

(64)

Rab6 interacting
protein 1

Rab6-Rab11 interaction

(483)

SH3TC2

Recycling endosome

(317)

Syntaxin 4A

t-SNARE, regulatator of secretion

(484)

Sec15

Exocyst component, endocytic
recycling

(474)

Rab11a-GDP

GDP dissociation
inhibitor 2

GDI

(448)

Rab11b-GTP
(neuron
specific)

myosin vb

Cargo recycling

(485)

Rabphilin-11

Vesicle recycling

(473)

Rab6 interacting
protein

Links Rab6 and Rab11

(483)

Cpn 0585

Facilitates Rab11b recruitment to
Cpn inclusion membrane

(440)

Evi5

Coordination of vesicular
trafficking, cytokinesis, and cell
cycle regulation

(319, 471)

Rab15 effector
protein

Regulates receptor recycling from
the recycling compartment

(328)

Cpn 0585

Facilitates Rab15 recruitment to
Cpn inclusion membrane

(440)

FIP1

Recycling

(475)

FIP2

Recycling

(475)

FIP3

Recycling

(475)

Myosin Vb

Motor

(486)

RIP11

Insulin granule exocytosis

(487)

Rab17

TBC1D7

GAP

(22, 446)

Rab21

alpha-integrin
subunit

Regulates vesicular motility of
integrins

(344)

Varp

GEF for Rab21

(488)

Rab15
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Rab22a

EEA1

May be linking Rab22a with early
endocytic pathways

(352)

Rabex-5

Links Rab22-Rab5 signaling
cascade

(356)

Rabenosyn-5

May be involved in endosomal
tethering

(489)

Rab23

EVI5-like

GAP

(22, 446)

Rab25

Integrin beta-1
subunit

Promotes cell migration

(359)

Rab27a

Exophilin4

Mediates the peripheral
localization of melanosome and
glucagon granules

(490-492)

Rab27a/b

Melanophilin

Mediates the peripheral
localization of melanosome and
glucagon granules

(493-496)

Rab27a-GDP

Granuphilin

Regulates dense-core vesicle
exocytosis

(497)

Rab27a/b

Rabphilin

Modulates secretory vesicle
exocytosis

(498)

Rab27a/b

Noc2

Modulates dense-core vesicle
exocytosis

(498, 499)

Rab27a/b

Munc13-4

Modulates dense-granule
secretion from platelets

(500)

Rab27a/b

Slp2a

Regulates melanosome transport

(490)

Rab32

Varp

Regulates Tyrp1 trafficking in
Melanocytes

(339, 346)

PKA

Regulates melanosome transport

(501)

ATG16L

Regulates autophagosome
formation involving Rab33a

(409)

GM130

May be involved in the docking
and fusion of vesicles in the Golgi
apparatus

(502)

Rabaptin-5

May be involved in the docking
and fusion of vesicles in the Golgi
apparatus

(502)

ATG16L

Regulates autophagosome
formation involving Rab33b

(410)

Rabex-5

May be involved in the docking
and fusion of vesicles in the Golgi
apparatus

(502)

RILP

Regulate lysosome

(379)

Rab33a

Rab33b

Rab34
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morphogenesis
Hmunc13

Mediates lysosome-Golgi
trafficking

(375)

Rab35

Fascin

May stimulate actin bundling

(388)

Rab36

RILP

Regulates spatial distribution of
late endosomes and lysosomes

(372)

GAPCenA

Acts as a GAP

(503)

Varp

Regulates Tyrp1 Trafficking in
Melanocytes

(346, 504)

Rab38
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APPENDIX C: Conformational state of Rab7 when bound to Rab7: Interaction
between CID1067700 and Rab7 does not cause transition of Rab7 to GTP conformation.
GST-RILP is mobilized on glutathione beads and then interaction between RILP and HisSUMO-GFP-Rab7 with Rab7 in the GTP bound state is measured using flow cytometry.
Incubation with either CID1067700 or GDP precludes interaction. Fluorescence output
from GFP is a measure of Rab7 binding.
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APPENDIX D. Rho GTPase (1). Key functions, (2). Some of the characterized GEFs
and GAPs, and (3). Association with cancer

Rho
GTPase
protein

Key function

Characterized
GEF

Characterized
GAP

Cancer link

Reference

Cdc42

Regulates
formation of and
filopodia,
maintenance of
cadherin-mediated
cell-cell adhesion

Dbs;
Intersectin,Tuba,
CopE, Fgd1,
Vav1/2/3,
Ephexin, Asef,
DOCK2/9

p50rhoGAP
(GMPPNP), nChimaerin

Breast,
melanoma,
squamous-cell
carcinoma
(SCC),
colorectal,
testicular

(180, 505-514)

Rac1a

Regulates cell
membrane
ruffling, formation
of lamellipodia,
maintenance of
cadherin-mediated
cell-cell adhesion

Tiam1, Vav1/2/3,
Ephexin, Trio,
Sos1/2, Asef,
Dock4

β2-chimaerin, nChimaerin,
ArhGAP15

Breast,
melanoma, SCC,
colorectal, lung,
testicular,
gastric, renal

(180, 193, 507,
511, 511-518).

Rac1b

Suspected to
promote cellular
transformation

Colon, breast

(207, 512, 519)

Rac2

Regulation of
NADPH oxidase
activity,

Head and neck
squamous-cell
carcinoma,
chronic
myelogenous
leukemia

(520-524)

Rac3

Regulates cell
invasion

Non-IBC

(512, 525)

DOCK2/9, P-Rex1
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RhoA

Regulates
formation of actin
stress fibers and
focal adhesions,
Implicated in
thrombin-, serum-,
and LPA-induced
neurite retraction
and cell rounding,
maintenance of
cadherin-mediated
cell-cell adhesion,
regulates
cytokinesis

XPLN, Vav1/2/3,
Ephexin, Syx,
p63RhoGEF,
Tech, Arhgef5,

RhoB

Mediates
apoptosis

RhoC

Modulates
induction of
angiogenic
factors

RhoD

Regulates cell
migration and
cytokinesis,

RhoE/Rnd3

Cytoskeletal
organization and
cell cycle
progression,
regulates activity
of RhoA

RhoG

Regulates
endothelial apical
cup assembly,
regulates the
neutrophil
NADPH oxidase,
regulates gene
expression and the

ARAP3,
MgcRacGAP

Colon, breast,
lung, testicular
germ cell, head
and neck
squamous-cell
carcinoma;
melanoma,
colorectal,
pancreas, lung,
testicular,
ovarian, gastric,
liver, pelvic
ureteric,
prostrate,
neuroblastona,
bladder,
leukemias AML,
sarcoma,
hepatocellular
carcinoma

(180, 511, 512,
520, 526-540)

XPLN

Breast, lung and
HNSCCa

(537, 541-546)

SmgGDS

Inflammatory
breast cancer,
pancreatic ductal
adenocarcinoma;
breast IBC; nonIBC; melanoma;
SCC; pancreas;
lung; non-small
cell lung cancer;
ovarian, gastric;
bladder;
Hodgkin's,
hepatocellular
carcinoma,
prostrate

(512, 539, 547550, 550-554)

(555, 556)

Trio
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Non-small cell
lung carcinoma

(557, 558)

Non-IBC

(512, 559, 560)

actin cytoskeleton
in lymphocytes

RhoH

Acts as an adaptor
molecule in TCR
signaling pathway

Non-Hodgkin’s
lymphoma,
multiple
myeloma
Diffuse large Bcell lymphomas

(512, 561, 562)

Rnd1/2/3

Regulates axon
guidance and
neurite extension,
regulates
formation of stress
fibers

Non-IBC

(512, 557, 563)
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Appendix E. Comparative functional effect of other NSAIDs on Rac1: i) Aspirin; ii)
Ibuprofen; iii) Fenoprofen; iv) Ketoprofen, do not show significant effect on membrane
localization of Rac1 GTPase in OVCA433 cells at similar concentration of treatment and
duration as R-Naproxen.
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
Appedix E (i): Relative to control (0.2 % DMSO), 300 µM of Aspirin does not cause
significant membrane redistribution of Rac1 in OVCA433 cells after 1hr of treatment.
This is unlike the case of R-Naproxen at the same concentration and duration of
treatment.
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Appedix E (ii): Relative to control (0.2 % DMSO) and also compared to R-Naproxen,
300 µM of Ibuprofen does not cause significant membrane redistribution of Rac1 in
OVCA433 cells after 1 h of treatment.
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Appedix E (iii): Relative to control (0.2 % DMSO), 300 µM of Fenoprofen does not
cause significant membrane redistribution of Rac1 to the cytosol in OVCA433 cells after
1 h of treatment unlike R-Naproxen at the same concentration and duration of treatment.
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Appedix E (iv): Relative to control (0.2 % DMSO), 300 µM of Ketoprofen does not
cause significant membrane redistribution of Rac1 in OVCA433 cells after 1 h of
treatment. Rac1 is still significantly present at the plasma membrane unlike the case of RNaproxen at the same concentration and duration of treatment.
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Appendix	
  F:	
  COX enzyme inhibitory activity of a panel of NSAIDs

COX-1

IC50 (M)

Compound

nH

1-6MNA

2.80E-05

1

2-R-Nap

7.20E-06

0.6

3-S-Nap

5.90E-08

0.9

Pub Chem: CID2950007

1.80E-06

0.9

5-R-Keto

9.90E-07

0.9

6-S-Keto

<1.0E-0.8

NA

1-6MNA

>1.0E-04

NA

2-R-Nap

4.20E-06

0.9

3-S-Nap

7.00E-08

1.3

Pub Chem: CID2950007

5.80E-07

0.8

5-R-Keto

>1.0E-04

NA

6-S-Keto

8.5E-0.8

1.4

COX-2
Compound

6-MNA: 6-Methoxy-2-naphthalene acetic acid
Assay performed through a contract agreement with CEREP, Seattle, U.S.A.	
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